Epithelial-mesenchymal transition phenotypes impact on metastases formation in metastatic breast cancer by Liu, Xiao
Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde 
Klinik der Ludwig-Maximilians-Universität München 
Direktor: Prof. Dr. med. Martin Canis 
 
 
 
 
 
 
 
Epithelial-Mesenchymal Transition Phenotypes Impact on Metastases 
Formation in Metastatic Breast Cancer 
 
 
 
 
 
 
 
 
 
Dissertation 
zum Erwerb des Doktorgrades der Humanbiologie 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  vorgelegt von 
    Xiao Liu 
    aus China 
       2020
 
1 
 
 
 
Mit Genehmigung der Medizinischen Fakultät der 
Universität München 
 
 
 
Berichterstatter: Prof. Dr. rer. nat. Olivier Gires 
 
Mitberichterstatter: Prof. Dr. med. Martin Angele 
                               Priv. Doz. Dr. Med. Ulrich Andergassen 
                               Prof. Dr. med. Claus Belka 
 
                                 
 
  
 
Dekan: Prof. Dr. med. dent. Reinhard Hickel 
 
 
Tag der mündlichen Prüfung: 09.06.2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
2 
 
Dean’s Office  
Medical Faculty  
 
 
 
 
 
Affidavit  
 
 
 
 
 
 
I, Xiao Liu, hereby declare that the submitted thesis entitled  
 
 
 
Epithelial-Mesenchymal Transition Phenotypes Impact on Metastases Formation in Metastatic 
Breast Cancer 
 
is my own work. I have only used the sources indicated and have not made unauthorised use of services 
of a third party. Where the work of others has been quoted or reproduced, the source is always given. 
 
I further declare that the submitted thesis or parts thereof have not been presented as part of an 
examination degree to any other university. 
 
 
 
 
 
 
 
 
 
     Munich, 12.08.2019 Xiao Liu 
Place, date Signature doctoral candidate 
 
 
 
 
  
CONTENTS 
1 
 
CONTENTS 
1. INTRODUCTION ....................................................................................................................... 1 
1.1 Breast cancer ........................................................................................................................... 1 
1.2 Tumor metastasis ..................................................................................................................... 3 
1.3 Epithelial to mesenchymal transition........................................................................................ 4 
1.4 EMT and cancer organotropism during metastasis formation ................................................... 5 
1.5 Epithelial cell adhesion molecule (EpCAM) ............................................................................ 6 
1.6 CTC enrichment ...................................................................................................................... 9 
1.7 Study design .......................................................................................................................... 10 
2. MATERIALS AND METHODS ................................................................................................. 12 
2.1 Materials ............................................................................................................................... 12 
2.1.1 Chemicals ....................................................................................................................... 12 
2.1.2 List of experimental kits .................................................................................................. 13 
2.1.3 List of antibodies ............................................................................................................. 13 
2.1.4 List of qRT-PCR primers ................................................................................................ 14 
2.1.5 List of cell lines ............................................................................................................... 16 
2.1.6 List of equipment ............................................................................................................ 19 
2.1.7 List of consumables ......................................................................................................... 20 
2.1.8 List of software applications ............................................................................................ 21 
2.2 Methods................................................................................................................................. 22 
2.2.1 Cell culture...................................................................................................................... 22 
2.2.2 Flow cytometry ............................................................................................................... 22 
2.2.3 Proliferation assay ........................................................................................................... 23 
2.2.4 Cell metabolism .............................................................................................................. 23 
2.2.5 Single cell deposition for single cell-derived clones......................................................... 23 
2.2.6 Transwell invasion assay ................................................................................................. 24 
2.2.7 Adhesion assay................................................................................................................ 24 
2.2.8 Endothelial adhesion assay .............................................................................................. 25 
CONTENTS 
2 
 
2.2.9 Chemoresistance assay .................................................................................................... 25 
2.2.10 2D colony formation assay ............................................................................................ 25 
2.2.11 3D soft agar colony formation assay .............................................................................. 26 
2.2.12 mRNA isolation ............................................................................................................ 26 
2.2.13 Reverse transcription polymerase chain reaction (RT-PCR)........................................... 27 
2.2.14 Quantitative Real-Time PCR (qRT-PCR) ...................................................................... 28 
2.2.15 Animal experiments ...................................................................................................... 29 
2.2.16.1 Clinical cohort ............................................................................................................ 33 
2.3 Statistical analysis ................................................................................................................. 35 
3. RESULTS ................................................................................................................................... 36 
3.1 The 4T1 MBC mouse model .................................................................................................. 36 
3.2 EMT in CTC1 cells is accompanied by increased migration, but reduced proliferation and 
tumor formation ability ................................................................................................................ 40 
3.3 EMT heterogeneity in DTC1-derived CTC lines .................................................................... 49 
3.4 Mesenchymal-type CTCs are more resistant to chemotherapy than epithelial-type CTCs ....... 54 
3.5 E/m-type CTCs possess highest lung metastasis formation ability in vivo .............................. 55 
3.6 EMT in CTC lines is not a mere reflection of cell heterogeneity in 4T1 and DTC1 cells ........ 59 
3.7 EpCAM expression is negatively correlated with EMT .......................................................... 61 
3.8 EpCAM expression is higher in metastatic sites compared with primary tumors .................... 61 
3.8 The EpCAM-positivity rates in DTCs is related to metastasis and predicts survival in patients 
with MBC ................................................................................................................................... 64 
4. DISCUSSION ............................................................................................................................. 71 
4.1 The 4T1 metastatic mouse model ........................................................................................... 71 
4.2 EMT phenotypes of DTC-derived CTC lines ......................................................................... 73 
4.3 E/m-type CTCs have the highest capacity to form lung metastasis ......................................... 75 
4.4 The influence of EMT on metastasis ...................................................................................... 77 
4.5 EpCAM expression during tumor metastasis .......................................................................... 79 
4.6 Characterization of CTCs and DTCs isolated by SE-iFISH .................................................... 80 
5. CONCLUSIONS......................................................................................................................... 83 
CONTENTS 
3 
 
5.1. Summary .............................................................................................................................. 83 
5.2. Zusammenfassung .............................................................................................................. 84 
6. REFERENCES ........................................................................................................................... 85 
7. LIST OF FIGURES .................................................................................................................. 100 
8. TABLE LIST ............................................................................................................................ 102 
9. ABBREVATIONS .................................................................................................................... 103 
10. PUBLICATIONS .................................................................................................................... 106 
11. ACKNOWLEDGEMENTS ..................................................................................................... 107 
 
 
 
 
 
 
 
INTRODUCTION 
1 
 
1. INTRODUCTION 
1.1 Breast cancer 
Cancer is a life-threatening disease worldwide. It was reported that in 2019, 1,762,450 patients will be 
newly diagnosed with carcinoma and 606,880 tumor-related deaths are estimated to be registered in 
the United States (Siegel et al., 2019). Breast cancer is the leading cancer type in women (Siegel et al., 
2019). Owing to early detection techniques and improved therapy methods, the mortality of breast 
cancer patients has decreasing by 40% over the past 30 years (DeSantis et al., 2017). Once breast 
cancer is suspected, mammography, magnetic resonance imaging (MRI), and tissue biopsy can be used 
to further diagnose (Breast Cancer Treatment (PDQ®): Health Professional Version (2002)). The 
American Cancer Society (ACS) highly recommends that women who have reached 45 years of age 
should start regular mammography screening. Women aged ≥ 55 years should have annual screening 
for breast cancer (Oeffinger et al., 2015; Smith et al., 2019). Screening mammography could contribute 
to a 19% decrease of cancer mortality, for women over 60 years breast cancer mortality was even 
reduced by 32% through mammography (Pace and Keating, 2014). 
Final diagnosis of breast cancer is always dependent on further evidence of pathology departments. 
When breast cancer is assured, staging breast cancer is the next step that is undertaken to help 
physicians determining the appropriate treatment that should be given to the patients. The TNM staging 
system is comprised of the physical extent of the tumor and nodal and distant metastases, where T 
stands for the primary tumor (range fromT0 to T4), N is the status of tumor invasion of nearby lymph 
nodes (range from N0 to N3), and M means distant metastasis (i.e. lung, liver, kidney, bone; either M0 
or M1) (Sobin LH, 2009). 
According to molecular and phenotypic characteristics, breast cancer can be further classified into 3 
group: 
• The Luminal-type, where tumors express hormone receptors (i.e. estrogen (ER) or 
progesterone receptor (PR)). Patients with the luminal subtype can receive endocrine therapy.  
• The HER2-type, where tumors over-express the human epidermal growth factor receptor 2 
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(HER2). ER and PR receptor can be positive or negative. This subtype can receive HER2-
targeted therapy.  
• The basal-type, or Triple Negative (TN), which comprises tumors that are negative for all three 
major receptor types, i.e. HER2, estrogen and progesterone receptors (Sobin LH, 2009). 
The management of breast cancer includes surgery, medication, and radiation (Goetz et al., 2019). 
Surgery is the essential management for breast cancer that comprises the standard surgical 
interventions mastectomy (excision of the entire breast), quadrantectomy (remove a one-quarter part 
of the breast), and lumpectomy (cut out the primary tumor) (McDonald et al., 2016). Medication 
includes hormone blocking therapy, chemotherapy, and application of monoclonal antibodies. For 
patients who have a high predicted probability of tumor recurrence, an adjuvant chemotherapy, which 
is chemotherapy after definitive surgery, should generally be considered (McDonald et al., 2016). 
Patients with high expression of HER2 in their primary tumors are eligible for an adjuvant treatment 
with HER2-specific monoclonal antibodies (i.e trastuzumab). Similarly, for patients with ER or PR 
positive breast tumors, related hormone blocking treatment is recommended (McDonald et al., 2016; 
Warrier et al., 2016). Patients with an advanced tumor stage (i.e. tumor size larger than 5 cm or fixed 
to the chest wall) would benefit from neoadjuvant therapy (medical intervention before surgery) 
(McDonald et al., 2016). Neoadjuvant treatment can help to release tumor burden, so that patients can 
become eligible for surgical excision of the primary tumor (Leal et al., 2015). 
The patients’ outcome depends on several factors including age, tumor stage, and tumor subtype. For 
patients at tumor stages I to III, which means they suffer from primary breast cancer without or with 
invasion of regional lymph nodes, but no distant metastases, 5-year overall survival rates are generally 
good (above 70%) (Kang and Pantel, 2013; Lim and Hortobagyi, 2016). In contrast, patients with 
distant metastasis (i.e. lung, liver, bone), which is referred to as tumor stage IV, have a 5-year survival 
of less than 25% (Kang and Pantel, 2013; Lim and Hortobagyi, 2016). Therefore, improving the 
management of patients with metastases would have a great influence on breast cancer patients’ 
survival (Rashid and Takabe, 2014).  
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1.2 Tumor metastasis  
Despite the expansion of new technologies and therapeutic methods, the development of metastases 
remains the major threat with significant impact on the patients’ overall survival until today (Liu et al., 
2017). The “seed and soil” theory describes the process of metastases formation and is widely cited 
and accepted. The initial step during the formation of distant metastasis resides in the release of single 
tumor cell or cell clusters from the primary tumor sites, which eventually intravasate into the blood 
stream; when carcinoma cells are in blood stream, they are called circulating tumor cells (CTCs) 
(Azevedo et al., 2015). Most of the CTCs will be under immune surveillance and will be recognized 
and eradicated by cells of the immune system. Only a small proportion of carcinoma cells can survive 
in the blood stream, succeed in extravasating, and finally disseminate to distant sites. Tumor cells that 
have settled in distant sites are then called disseminated tumor cells (DTCs) (Massague and Obenauf, 
2016). DTCs are generally regarded as the major source of metastatic outgrowth and tumor relapse 
(Chaffer and Weinberg, 2011; Joosse et al., 2015; Lambert et al., 2017). 
One study showed that even small tumors could release millions of tumor cells in the circulation, yet 
a lot of cancer patients never relapse, or develop metastases after a long time of latency (Nagrath et 
al., 2007). This suggests that metastasis formation is, at the single cell level, a rather inefficient process. 
In other words, metastasis initiating cells (MIC) originate from CTCs and DTCs, but only represent a 
proportion of the entire CTC/DTC population that is released from primary tumors. In the seed and 
soil hypothesis, low efficiency of metastatic colonization is explained by the fact that the distant “soil” 
might not be compatible with a foreign “seed”, referring to differences between local and distant 
microenvironments. In fact, the most favorable soil may be the primary tumor site itself (Kim et al., 
2009). In 2009, Kim and colleagues first described the preferential re-seeding of CTCs back to the 
primary tumor site or existing metastasis, over homing to tumor-free sites, and termed this process 
tumor “self-seeding” (Kim et al., 2009). The self-seeding program might enhance tumor malignancy 
via a renewed seeding of the most aggressive and therapy resistant cell clones in primary site or in 
metastases (Kim et al., 2009; Obenauf et al., 2015) 
CTCs are termed DTCs after their successfully homing to distant sites, for instance, in the bone 
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marrow, lungs, spleen, etc. When and where metastases develop, may differ substantially depending 
on the heterogeneity of primary and systemic tumor cells, tumor types, treatment, and individual 
patients (Chambers et al., 2002; Dasgupta et al., 2017). Therefore, detecting and characterizing the 
actual functions and metastatic capacity of CTCs and DTCs could broaden our knowledge of 
metastasis formation, and eventually improve therapeutic regimens. 
1.3 Epithelial to mesenchymal transition 
Epithelial to mesenchymal transition (EMT) is known as a cellular program, through which epithelial 
cells can transdifferentiate to adopt a mesenchymal phenotype (Hay, 1995). During embryonic 
development, EMT allows cells to relocate within the embryo and, ultimately, to form the three germ 
layers, endo-, meso-, and ectoderm, which will further differentiate to form the mature organism (Kim 
et al., 2017). In cancer progression, EMT is considered to associate with various tumor functions, 
containing the malignant progression, the generation of cancer stem cell, tumor cell migration, 
intravasation and extravasation from blood vessels, metastasis formation, and resistance to treatment 
(Huang et al., 2013; Pastushenko and Blanpain, 2019; Pastushenko et al., 2018; Thiery and Lim, 2013; 
Ye et al., 2017). Importantly, through EMT cancer cells are equipped with increased migratory and 
invasive abilities, which could be beneficial for the initial steps of metastasis (Lambert et al., 2017). 
Recent studies demonstrated that, instead of adopting extreme epithelial or mesenchymal phenotypes, 
carcinoma cells rather undergo a more fluid transition, where cells can adopt a hybrid and more 
intermediate E/M phenotype (Brabletz et al., 2018b; Campbell, 2018). 
The function of EMT in the metastatic process is, however, still in debate. Zheng et al. showed that 
pancreatic cancer cells could form lung metastasis even when the two EMT-inducing transcription 
factors Twist1 and Snai1 were deleted (Zheng et al., 2015). Similarly, Fischer et al. have shown that 
the overexpression of micro-RNA mir-200, which inhibits EMT, had no influence on lung metastasis 
formation (Fischer et al., 2015). Particularly these two publications have sparked a vivid discussion 
and debate on the role of EMT in tumor metastases (Brabletz et al., 2018b; Derynck and Weinberg, 
2019; Ye et al., 2017). 
At the molecular level, EMT is under the control of multiple pathways, including transforming growth 
INTRODUCTION 
5 
 
factor β (TGF-β), the Wnt pathway and β-catenin, the Notch signaling pathway, and tyrosine kinases 
receptors (e.g. EGFR) (De Francesco et al., 2018; Gonzalez and Medici, 2014; Moustakas and Heldin, 
2016; Wu et al., 2016; Zhang et al., 2016). Eventually, EMT is induced by a set of core EMT 
transcription factors (EMT-TFs) including Snail, Slug, Zeb1 and 2, and Twist1 (Kalluri and Weinberg, 
2009; Stemmler et al., 2019; Tam and Weinberg, 2013). Multiple genes of the above-mentioned 
pathways and of the core EMT-TFs directly participate in the regulation of EMT. Epithelial proteins 
like E-cadherin, Cytokeratins, Claudins, Rab25, and Occludin, play important roles in maintaining 
epithelial features of cells, like promoting cell-cell contact formation and cell proliferation. EMT-TFs 
can influence the expression of epithelial (i.e. E-cadherin, Cytokeratins) and mesenchymal (i.e. 
Vimentin) proteins, thus, regulating the EMT statuses of cells (Brabletz et al., 2018b; Gonzalez and 
Medici, 2014). As a result, a down-regulation of E-cadherin can lead to a significant loss of the 
adhesive ability of cells and, in turn, can reduce cell-cell contacts. Recently, it was reported that small, 
non-coding RNAs had an effect on the EMT program. For example, miR-9 can inhibit the expression 
of E-cadherin and promote EMT, while the miR-200 family can interact with ZEB1/2 and suppress 
EMT (Yan et al., 2013). 
1.4 EMT and cancer organotropism during metastasis formation 
Different cancer types have differing preferential metastatic organs, i.e. patients with MBC frequently 
have bone and lung metastases, colon cancer preferentially metastasize in the liver, whereas patients 
with lung cancer frequently develop brain metastasis. This is also known as organotropism during 
metastasis formation (Gao et al., 2019; Nan et al., 2019; Siegel et al., 2019). Recent studies showed 
that the development of organotropism during the metastatic process depended on the tumor cells’ 
intrinsic properties, the distinct organ microenvironment, and the interaction between carcinoma cells 
and distant organs (Akhtar et al., 2019; Chen et al., 2018; Nan et al., 2019). For instance, patients with 
breast cancer can develop metastasis in multiple sites (i.e. bone, liver, and lung), which reflects the 
fact that cells in individual primary tumors have distinct abilities to metastasize in different organs. 
Furthermore, some organs are more difficult for tumor cells to access and to settle in. For example, the 
blood-brain barrier, which is made up of tightly connected endothelia, astrocytes, and pericytes, can 
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hinder the invasion of tumor cells from numerous cancers (Dong, 2018).  
Cell-cell adhesive interactions can also influence organotropism during metastasis formation (Chen et 
al., 2018). During the EMT procedure, cancer cells will frequently decrease the expression of E-
cadherin, and in parallel enhance N-cadherin expression (Gloushankova et al., 2017), which is referred 
to as the “cadherin switch”. E-cadherin plays a key role in tight cell-cell junctions in epithelial cells, 
while N-cadherin directly mediates homotypic and heterotypic cell-cell adhesion, and is predominantly 
expressed in neural, endothelial, and stromal cells (Chen et al., 2018; Gloushankova et al., 2017; 
Mrozik et al., 2018). Recent studies demonstrate that tumor cells can acquire partial or hybrid EMT 
phenotypes, which means epithelial and mesenchymal markers, including different cadherins, can co-
exist in individual cells (Jordan et al., 2011; Pastushenko and Blanpain, 2019; Tan et al., 2014). 
CTCs/DTCs are considered as the source of metastatic seeds. Theoretically, CTCs/DTCs with a hybrid 
EMT phenotype may adapt more easily to the distant microenvironment by, for example, transiently 
changing their expression of cadherins (E- or N- cadherin). Such changes could allow them to tighten 
or release contacts to cells of various microenvironments, and thus to better cope with changing 
conditions along the metastatic cascade. In the last decade, many efforts have been made to capture 
and characterize CTCs and, to lesser extent, DTCs of various tumor types. However, the biological 
characterization and capture of CTCs and DTCs are still technically challenging (Gabriel et al., 2016). 
In most CTC isolation techniques, CTCs are captured through the enrichment of rare epithelial cells 
from blood, by using epithelial markers, e.g. epithelial cell adhesion molecule (EpCAM). Despite 
being of great value for further prognosis of patients, these techniques might preferentially enrich 
epithelial cells, thus introducing a bias in the actual nature of CTCs that are enriched. Therefore, 
EpCAM-dependent CTC enrichment technologies do not allow to study the full spectrum of systemic 
tumor cells. Hence, the actual contribution of EMT to metastasis formation remains only partially 
addressed. 
1.5 Epithelial cell adhesion molecule (EpCAM) 
EpCAM was first described by Herlyn et al. in 1979 and it was recognized as a humoral antigen that 
is highly expressed in human colon cancer (Herlyn et al., 1979). EpCAM is a membrane protein with 
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an apparent molecular weight of 30- to 40-kDa, and which was found expressed in most epithelial 
tissues and epithelial tumors (Imrich et al., 2012; Munz et al., 2009). EpCAM consists of a large 
extracellular domain (EpEX) and a small intracellular domain (EpICD) connected by a single 
transmembrane domain (Maetzel et al., 2009). Since its first description in 1979, numerous cellular 
functions have been assigned to EpCAM, ranging from the name-giving cell adhesion property, 
regulation of proliferation, maintenance of morphological and epithelial integrity, and regulation of 
cell differentiation, including the maintenance of the pluripotency of progenitor and embryonic stem 
cells (Gonzalez et al., 2009; Huang et al., 2011; Lu et al., 2010; Sarrach et al., 2018; Wang et al., 
2018b; Wu et al., 2013). EpCAM signaling, which is required for its mitogenic and pluripotency-
maintaining capacities, is initiated by regulated intramembrane proteolysis (RIP) (Maetzel et al., 2009; 
Munz et al., 2009). This cleavage is initiated by shedding of the extracellular domain EpEX by ADAM 
proteases, which generates a membrane-tethered C-terminal fragment (CTF) of EpCAM. EpCAM-
CTF, as a substrate of the gamma-secretase complex, can be cleaved to release the EpICD part into 
the cytoplasm. EpICD can further form a complex together with FHL2, β-catenin, and Lef1, which 
can translocate in the cell ś nucleus to further regulate gene expression (i.e. C-myc, Cyclin D1, 
amongst others) (Chaves-Perez et al., 2013; Huang et al., 2011; Maetzel et al., 2009; Munz et al., 
2009). 
More recently, a spatiotemporal regulation of EpCAM expression has been determined during the 
three-dimensional differentiation of pluripotent embryonic stem cells (ESC). EpCAM was shown to 
be entirely lost in mesodermally differentiating cells at an early time point of gastrulation, while it was 
retained in endodermal cells (Sarrach et al., 2018). Further analysis disclosed that both, EpCAM-
negative and -positive cells are required to ensure proper differentiation of mesodermal cells, for 
example in order to terminally differentiate into contracting cardiomyocytes (Sarrach et al., 2018). 
Hence, EpCAM is a transmembrane protein with multiple functions in stem and epithelial cells. 
In order to fulfil these functions, EpCAM can interact with other cell adhesion molecules and influence 
adhesive structures between cells and cell-matrix (Wu et al., 2013). For instance, the transmembrane 
domain can interact with claudin-7, and the reduction of EpCAM expression leads to a decrease of 
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Claudin-7 protein expression, too (Ladwein et al., 2005). EpCAM can enhance the proliferation of 
carcinoma cells and accordingly a down-regulation of EpCAM expression can cause the decrease of 
proliferation in FaDu cells (Maetzel et al., 2009; Munz et al., 2004). Previously, a study demonstrated 
that EpCAM can crosstalk with the Phosphatase and Tensin Homolog (PTEN)/Protein Kinase B 
(AKT)/Mechanistic target of Rapamycin Kinase (mTOR) pathway and regulates EMT, metastatic 
formation, and stemness in nasopharyngeal cancer through interaction with (Wang et al., 2018b).  
Apart from epithelial cells, embryonic stem cells and precursor cells also express EpCAM (Balzar et 
al., 1999; Gires and Stoecklein, 2014; Gonzalez et al., 2009; Lu et al., 2010; Sarrach et al., 2018). On 
the base of a strong and frequent expression of EpCAM in epithelial cancer cells and because it 
represents a marker for epithelial cells which is lacking on blood cells, EpCAM is the most widely 
used membrane-associated anchor molecule to detect CTCs from blood cells (Banko et al., 2019; Gires 
and Stoecklein, 2014; Went et al., 2004). However, in analogy to its spatiotemporal expression in ESC 
and during embryonic differentiation, the first prove of a dynamic expression of EpCAM in human 
CTCs originated from a xenograft mouse model, where cells that had undergone EMT had lost the 
expression of EpCAM (Gorges et al., 2012). The dynamic regulation of EpCAM expression in tumor, 
especially in systemic cancer cells, has been addressed in a review paper by Wang at al. in 2017, who 
compiled the knowledge on EpCAM repression during EMT. Here, the general consensus is that EMT 
is accompanied by a loss of epithelial markers, including EpCAM. Beyond such concomitant loss, a 
causal role of EpCAM in the regulation of EMT is currently addressed more thoroughly. Hsu et al. 
described an EGFR-dependent cleavage of EpCAM in an endometrial cell line to generate an 
intracellular domain EpICD that actively induces EMT at the transcriptional level (Hsu et al., 2016). 
Such cleavage of EpCAM is based on regulated intramembrane proteolysis, as described by Maetzel 
et al. However, the described EGFR-dependent cleavage of EpCAM was neither observed in several 
head and neck, breast, colon, and prostate cancer cell lines, nor in the published RL95-2 endometrial 
cell line. In sharp contrast, the soluble ectodomain of EpCAM was described as a novel EGFR ligand 
that counteracts EGF-mediated EMT in head and neck squamous cell carcinomas (Pan et al., 2018). 
Despite opposing results on the functions of EpCAM in EMT, it is ultimately of importance to note 
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that the reported loss of EpCAM during EMT in combination with its use as a marker to capture CTCs 
from the blood could hamper the study of CTCs that have undergone EMT and lost EpCAM expression 
(Wang et al., 2017a). 
1.6 CTC enrichment 
The presence of CTCs can serve as “liquid biopsy” to obtain instant information about systemic cancer 
in patients (Wang et al., 2017a). The CELLSEARCH® system is the first US Food and Drug 
Administration (FDA)-certified EpCAM-based CTC detection system (Gabriel et al., 2016; Liljefors 
et al., 2005). CELLSEARCH® is an immunofluorescence-based method in which CTCs are enriched 
with EpCAM-specific antibodies from the peripheral blood and are further defined as cells with nuclei 
(the nuclear marker, 4′,6-diamidino-2-phenylindole (DAPI) is positive), that express epithelial markers 
(i.e. Cytokeratin, EpCAM) and lack the leukocyte marker CD45. In 2004, Allard et al. first 
demonstrated that CELLSEARCH® could be used to evaluate CTCs numbers in cancer patients, and 
a cutoff value of ≥ 2 CTCs was determined to distinguish healthy or non-malignant disease from cancer 
(Allard et al., 2004). From then on, plenty of studies have been conducted to investigate the prognostic 
ability of CELLSEARCH-detected CTCs in various tumor types and most of them showed promising 
results. Generally, comparably low cutoff values such as 1-5 cells per 7.5 mL of peripheral blood 
correlated with reduced overall survival (Cohen et al., 2008; Cristofanilli et al., 2004; de Bono et al., 
2008; Gradilone et al., 2011; Janni et al., 2016b; Wang et al., 2016). 
Recently, more attention was paid to the significance of EpCAM-negative CTCs, which are considered 
as CTCs with a more mesenchymal phenotype. It was reported that mesenchymal CTCs were related 
to poor response to treatment and tumor progression in patients with MBC (Bednarz-Knoll et al., 2012; 
Fischer et al., 2015; Yu et al., 2013). However, EpCAM-dependent CTC isolation methods are not 
suitable for the isolation of these mesenchymal CTCs that have undergone EMT. Accordingly, the 
development of non–EpCAM-based CTC capture techniques would benefit the isolation and detection 
of cells that underwent EMT. Currently, EpCAM-independent CTC isolation methods include 
microfiltration, immunomagnetic methods, and microchip technologies (Chikaishi et al., 2017; Gabriel 
et al., 2016). On the basis of a usually larger size of carcinoma cells than erythrocytes and leukocytes, 
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microfiltration enrichment methods capture CTC through enriching large size cells (Gabriel et al., 
2016; Khetani et al., 2018). Immunomagnetic methods are based on the interaction of antigen-antibody 
and use antibody-conjugated magnetic beads to interact with specific antigens on the cell surface 
(Gabriel et al., 2016). Microchip technology uses a microfluidic device comprising antibody-
functionalized (i.e. EGFR, prostate-specific antigen, HER-2) micro-posts to interact with the CTC 
surface and thus enables non-invasive isolation (Gabriel et al., 2016; Stott et al., 2010). The subtraction 
enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH) is an antigen-
independent CTC enrichment strategy (Lin, 2015). By detecting aneuploid CTCs with abnormal 
numbers of Centromere 8, SE-iFISH can capture CTCs regardless of EpCAM expression (Ge et al., 
2015; Lin, 2015; Wang et al., 2018a). These EpCAM-independent CTC capture techniques provide 
new opportunities to detect both EpCAM positive and negative CTCs. 
1.7 Study design 
CTCs and DTCs are accepted as main sources of MICs that give rise to life-threating metastases in the 
course of cancer progression. As both, primary and systemic tumor cells, can undergo EMT to variable 
degrees, the question emerged as to which degree of EMT-associated changes in carcinoma cells 
promotes the formation of distant metastases (Aiello et al., 2017; Brabletz et al., 2018a; Ye et al., 
2017). One major aim of our study was therefore to investigate EMT phenotypes and their influence 
on the metastasis formation capacity of systemic cancer cells in the 4T1 breast cancer mouse model. 
A further aim was to assess whether EpCAM expression in CTCs and DTCs could be used as a 
surrogate marker to define the EMT status of clinical samples of systemic tumor cells and to predict 
the outcome of patients with MBC. 
To do so, 4T1 murine breast cancer cells were subcutaneously transplanted in the flank of BABL/c 
mice. Following the formation of primary tumors and the subsequent development of metastases, 
primary tumors, blood, bones, and organs (lung, liver, kidney, spleen) were collected and 4T1-derived 
cells were selected ex vivo. EMT phenotypes of systemic, 4T1-derived CTCs/DTCs were defined in 
vitro and their influence on proliferation, adhesion, migration, invasion, and tumor and metastases 
formation ability were analyzed in vitro and, following subcutaneous and intravenous re-
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transplantation, in vivo. In a clinical setting, the EpCAM-independent CTCs/DTCs isolation technique 
SE-iFISH was used to analyze the proportion of EpCAM-positive cells in blood and bone marrow of 
patients with MBC (n = 34). In order to assess whether the expression of EpCAM, as a surrogate 
marker for the EMT status of carcinoma cells, could predict the clinical outcome of patients, EpCAM 
expression proportion were correlated to the metastatic statuses and clinical outcome of patients with 
MBC.  
MATERIALS AND METHODS 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals  
 Table 1 List of chemicals    
 
Chemicals Company 
  
6-Thioguanine Sigma, Saint Louis, USA 
  
Agarose Biosciences, Heidelberg, Germany 
  
Ammonium chloride-based lysis reagent BD Pharm Lyse™, BD Biosciences, 
 Heidelberg, Germany 
Calcein-AM PromoKine/PromoCell GmbH, Heidelberg 
  
Cisplatin Santa Cruz Biotechnolog, Heidelberg, 
 Germany 
Collagenase Sigma, Steinheim, Germany 
  
Crystal Violet Sigma, Saint Louis, USA 
  
4′,6-diamidino-2-phenylindole (DAPT) Sigma-Aldrich GmbH, Taufkirchen 
  
Deoxyribonuclease (DNase) Sigma, Steinheim, Germany 
  
Doxorubicin Sigma, Steinheim, Germany 
  
Dulbecco’s Modified Eagle Medium (DMEM 
4,5 g/L glucose/with L-glutamine) 
Biochrom AG, Berlin, Germany 
 
Fetal bovine serum (FBS) Biochrom AG, Berlin, Germany 
  
Ethanol Abcam, Cambridge, UK 
  
Gelatin Sigma, Saint Louis, USA 
  
Matrigel Becton Dickinson, Heidelberg, Germany 
  
3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution 
Sigma, Saint Louis, USA 
  
Penicillin-Streptomycin Biochrom AG, Berlin, Germany 
  
 Phosphate buffer saline (PBS) Apotheke Klinikum Großhadern, München  
  Germany  
 Propidiumiodid (PI) Sigma-Aldrich GmbH, Taufkirchen  
    
 Tumor necrosis factor alpha (TNF-α) Thermo Fisher Scientific, Bleiswijk,  
  Netherlands  
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2.1.2 List of experimental kits 
 Table 2 List of experimental kits 
Products Company 
Light Cycler 480 SYBR Green I Master, Roche Mannheim, Germany 
QiaShredder Qiagen, Hilden, Germany 
QuantiTect Reverse Transcription Kit Qiagen, Hilden, Germany 
RNeasy Kit Qiagen, Hilden, Germany 
 
2.1.3 List of antibodies 
 
Table 3 List of antibodies 
 
 
 
 
 
 
 
 
 
 
 
 
Chemicals Company 
Trypsin Biochrom AG, Berlin, Germany 
  
Triton-X 100 Sigma-Aldrich GmbH, Taufkirchen 
  
Antibodies Species Company 
Anti-mouse EpCAM Rat IgG2a,κ Becton Dickinson, Heidelberg, Germany 
 cloneG8.8  
Anti-mouse CD45 Rat IgG2b, κ BD Pharmingen, Heidelberg, Germany 
 30-F11  
Anti-mouse E-Cadherin Rabbit IgG, 
clone24E10 
Cell Signaling Technology, Danvers, 
USA 
  
Anti-mouse Vimentin Rabbit Monoclonal 
IgG, EPR3776 
Abcam, Cambridge, USA 
  
Anti-mouse Cytokeratin Rabbit polyclonal Invitrogen, Waltham, USA 
   
Fluorescein rabbit-anti-rat IgG (H&L) BD bioscience, Heidelberg, Germany 
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2.1.4 List of qRT-PCR primers 
Primers Sequences 
Ddr1 
FW: 5'-TCC ATA GAC CAG AGG GAT C-3' 
BW: 5'-CAG GGC ATA GCG GCA CTT GG-3 
E-cadherin 
FW: 5'-CAG GTC TCC TCA TGG CTT TGC-3' 
BW: 5'-CTT CCG AAA AGA AGG CTG TCC-3' 
Epcam 
FW: 5'-CAG TGT ACT TCC TAT GGT ACA CAG AAT ACT-3' 
BW: 5'-CTA GGC ATT AAG CTC TCT GTG GAT CTC ACC-3' 
Erbb-2 
FW: 5'-TCC CCA GGG AGT ATG TGA GG-3' 
BW: 5'- GAG GCG GGA CAC ATA TGG AG-3' 
Erbb-3 
FW: 5'-GCC CAA TCC TAA CCA GTG CT-3' 
BW: 5'-AGC CTG TAA TCT CCC GGA CT-3' 
Grlh1 
FW: 5'- GCT GAG ACA CTG GAA GTA CTG-3' 
BW: 5'-CGT GAA GGA AAT GGC GTT ATA AG-3' 
Gusp 
FW: 5'-CAA CCT CTG GTG GCC TTA CC-3' 
BW: 5'-GGG TGT AGT AGT CAG TCA CA -3' 
Krt19 
FW: 5'-CTA CCT TGC TCG GAT TGA GGA G-3' 
BW: 5'- AGT CTC GCT GGT AGC TCA GAT G-3' 
N-cadherin 
FW: 5'-AGG GTG GAC GTC ATT GTA GC-3' 
BW: 5'-CTG TTG GGG TCT GTC-3' 
Rab25 
FW: 5'-TGA GCC AAG ATG GGG AAT CG-3' 
BW: 5'-GGA GAA CTC AAC CCC GAT GG-3' 
Slug 
FW: 5'-TCC CAT TAG TGA CGA AGA-3' 
BW: 5'-CCC AGG CTC ACA TAT TCC-3' 
Snail 
5'-GCG GAA GAT CTT CAA CTG CAA ATA TTG TAA C-3' 
5'-GCA GTG GGA GCA GGA GAA TGG CTT CTC AC-3' 
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Table 4 qRT-PCR primers 
  
Primers Sequences 
Twist 
FW: 5'-CGG GTC ATG GCT AAC GTG-3' 
BW: 5'-CAG CTT GCC ATC TTG GAG TC-3' 
Vimentin 
FW: 5'-CGG AAA GTG GAA TCC TTG CA-3' 
BW: 5'-CAC ATC GAT CTG GAC ATG CTG T-3' 
Zeb1 
FW: 5'-CCA TAC GAA TGC CCG AAC T-3' 
BW: 5'-ACA ACG GCT TGC ACC ACA-3' 
Zeb2 
FW: 5'-CCG TTG GAC CTG TCA TTA CC-3' 
BW: 5'-GAC GAT GAA GAA ACA CTG TTG TG-3' 
MATERIALS AND METHODS 
16 
 
 
2.1.5 List of cell lines 
Cell lines Description 
4T1 Mouse breast cancer cell 
NIH3T3 Mouse Fibroblasts 
WEHI-231 Mouse B cell lymphoma 
bEnd.3 Mouse endothelialpolyoma middle T antigen transformed 
CTC1 4T1-derived CTC line 
DTC1 4T1-derived DTC line 
CTC8-1 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-5 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-6 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-12 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC6-11 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-6 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC7-1 DTC1-derived CTC line (from mouse number DTC1-7) 
CTC10-1 DTC1-derived CTC line (from mouse number DTC1-10) 
CTC10-2 DTC1-derived CTC line (from mouse number DTC1-10) 
CTC8-2 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-3 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-8 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-11 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-13 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-14 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC8-15 DTC1-derived CTC line (from mouse number DTC1-8) 
CTC6-4 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-5 DTC1-derived CTC line (from mouse number DTC1-6) 
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Cell lines Description 
CTC6-6 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-9 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-10 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-12 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-13 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-14 DTC1-derived CTC line (from mouse number DTC1-6) 
CTC6-15 DTC1-derived CTC line (from mouse number DTC1-6) 
DTC1-7-1 DTC1-derived DTC line (from mouse number DTC1-7) 
DTC1-7-3 DTC1-derived DTC line (from mouse number DTC1-7) 
DTC1-7-4 DTC1-derived DTC line (from mouse number DTC1-7) 
DTC1-7-5 DTC1-derived DTC line (from mouse number DTC1-7) 
DTC1-7-6 DTC1-derived DTC line (from mouse number DTC1-7) 
DTC1-8-1 DTC1-derived DTC line (from mouse number DTC1-8) 
DTC1-8-4 DTC1-derived DTC line (from mouse number DTC1-8) 
DTC1-8-5 DTC1-derived DTC line (from mouse number DTC1-8) 
DTC1-8-8 DTC1-derived DTC line (from mouse number DTC1-8) 
DTC1-8-9 DTC1-derived DTC line (from mouse number DTC1-8) 
4T1-PT1 4T1-derived primary tumor cell line (from mouse number 4T1-1) 
4T1-PT2 4T1-derived primary tumor cell line (from mouse number 4T1-2) 
4T1-PT3 4T1-derived primary tumor cell line (from mouse number 4T1-3) 
4T1-PT4 4T1-derived primary tumor cell line (from mouse number 4T1-4) 
4T1-PT5 4T1-derived primary tumor cell line (from mouse number 4T1-5) 
4T1-PT6 4T1-derived primary tumor cell line (from mouse number 4T1-6) 
4T1-PT7 4T1-derived primary tumor cell line (from mouse number 4T1-7) 
4T1-PT8 4T1-derived primary tumor cell line (from mouse number 4T1-8) 
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Table 5 List of cell lines 
Cell lines Description 
T1LM 4T1-derived lung metastasis cell line (from mouse number 4T1-1) 
T2LM 4T1-derived lung metastasis cell line (from mouse number 4T1-2) 
T3LM 4T1-derived lung metastasis cell line (from mouse number 4T1-3) 
T4LM 4T1-derived lung metastasis cell line (from mouse number 4T1-4) 
T2LNM 4T1-derived lymph node metastasis cell line (from mouse number 4T1-2) 
CTC1-PT1 CTC1-derived primary tumor cell line (from mouse number CTC1-1) 
CTC1-PT2 CTC1-derived primary tumor cell line (from mouse number CTC1-2) 
CTC1-PT3 CTC1-derived primary tumor cell line (from mouse number CTC1-3) 
CTC1-PT4 CTC1-derived primary tumor cell line (from mouse number CTC1-4) 
CTC1-7 LM CTC1-derived lung metastasis cell line (from mouse number CTC1-7) 
CTC1-9 LM CTC1-derived lung metastasis cell line (from mouse number CTC1-9) 
CTC1-15 LM CTC1-derived lung metastasis cell line (from mouse number CTC1-15) 
CTC1-10 SM CTC1-derived spleen metastasis cell line (from mouse number CTC1-10) 
D1PT DTC1-derived primary tumor cell line (from mouse number DTC1-1) 
D2PT DTC1-derived primary tumor cell line (from mouse number DTC1-2) 
D3PT DTC1-derived primary tumor cell line (from mouse number DTC1-3) 
D7KM DTC1-derived kidney metastasis cell line (from mouse number DTC1-7) 
D10LM DTC1-derived lung metastasis cell line (from mouse number DTC1-10) 
D10SM DTC1-derived spleen metastasis cell line (from mouse number DTC1-10) 
D8LM DTC1-derived lung metastasis cell line (from mouse number DTC1-8) 
D8KM DTC1-derived kidney metastasis cell line (from mouse number DTC1-8) 
D9LM DTC1-derived lung metastasis cell line (from mouse number DTC1-9) 
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2.1.6 List of equipment 
Table 6 List of equipment 
 
 
 
 
 
 
 
 
 
Equipment Company 
Autoclave Systec 95 Systec GmbH, Wettenberg, Germany 
Centrifuge Mikro 22R Hettich Lab Technology, Tuttlingen, Germany 
Centrifuge Rotanta 46 R Hettich Lab Technology, Tuttlingen, Germany 
ChemiDoc XRS+ imaging system BioRad, Hercules, USA 
Cell culture incubator HeraCell 240 Heraeus, Hanau, Germany 
Freezer (-20°C, -80°C) Liebherr, Ochsenhausen, Germany 
Laminar flow cabinet Heraeus Holding GmbH, Hanau, Germany 
Light Cycler 480 System Roche, Mannheim, Germany 
Microliter pipettes Gilson Inc., Middleton, USA 
Microplate reader Molecular Devices, Sunnyvale, CA, USA 
Microwave Sharp Electronics GmbH, Hamburg, Germany 
Nanophotometer Implen GmbH, München, Germany 
Phase contrast microscope “Axiovert 25” Carl Zeiss AG, Jena, Germany 
Power supply E835 Consort bvba, Turnhout, Belgium 
Thermomixer Comfort Eppendorf, Hamburg, Germany 
Water bath Exotherm U3e1 Julabo, Seelbach, Germany 
Flow cytometer “FACS-Calibur” BD Biosciences, Heidelberg, Germany 
Vortex Mixer IKA Works Inc., Wilmington, USA 
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2.1.7 List of consumables 
Products Company 
1.5 mL Tube (nuclease-free) Costar, New York, USA 
Micro Tube (1.5 mL/2 mL) Eppendorf AG, Hamburg, Germany 
Pipette Tips (10 μL, 20 μL, 100 μL, 
1000 μL) 
Starlab, Hamburg, Germany 
Safe seal tips professional 
(10 μL, 20 μL, 100 μL, 1000 μL)  
Biozym Scientific GmbH, Hessisch Oldendorf, 
Germany 
12-well plate (flat bottom) Nunc, Wiesbaden, Germany 
15 mL/50 mL Tube Becton Dickinson, Heidelberg, Germany 
24-well plate (flat bottom) Nunc, Wiesbaden, Germany 
40 um, 100 μm sterile filters Millipore, Wiesbaden, Germany 
6-well plate (flat bottom) Nunc, Wiesbaden, Germany 
96-well plate (flat bottom) Nunc, Wiesbaden, Germany 
96-well plate (round bottom) Nunc, Wiesbaden, Germany 
Cell culture flasks and dishes Nunc, Wiesbaden, Germany 
Corning® Costar® stripettes Sigma-Aldrich GmbH, Taufkirchen, Germany 
Cryo tubes Becton Dickinson, Heidelberg, Germany 
Cryomold Tissue-Tek®, Biopsy 
(10x10x5mm) 
Sakura Finetek, Staufen, Germany 
FACS-tubes Becton Dickinson, Heidelberg, Germany 
Gauge needle Microlance™ 3 Millipore, Schwalbach, Germany 
Gloves Sempermed, Vienna, Austria 
Microlance 3/23G, 3/24G Becton Dickinson, Heidelberg, Germany 
Neubauer chamber Sondheim, Rhön, Germany 
“Super Frost” slides Nunc, Wiesbaden, Germany 
Parafilm American National Can, Menasha, USA 
Quadriperm Sarstedt, Nümbrecht, Germany 
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Table 7 List of consumables 
2.1.8 List of software applications 
 
Table 8 List of software in present project 
Products Company 
Reagent reservoirs Costar, New York, USA 
Scalpels Feather/ PFM, Cologne, Germany 
Syringes Braun, Melsungen, Germany 
Transwell chambers (8 μm) Corning, Berdorf, US 
Software Company 
Adobe illustrator CC 2018 Adobe company, USA 
EndNote Thomson ResearchSoft, Stanford, USA 
BD Cell Quest Pro Version 5.2.1 Becton Dickinson, Heidelberg, Germany 
GraphPad Prism 5 GraphPad Software, Inc., San Diego, CA, USA 
Image J Wayne Rasband, Bethesda, USA 
LightCycler® 480 SW 1.5 Roche, Mannheim, Germany 
Microsoft Office 
(Word, PowerPoint, Excel) 
Microsoft, Redmond, WA, USA 
Photoshop CS6 Adobe Systems Inc., San Jose, USA 
SPSS SPSSInc., Chicago, USA 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.2 Cell culture medium 
Standard culture medium was prepared as Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10 % fetal bovine serum (FBS) and 1 % penicillin/streptomycin. Selection medium 
is based on standard culture medium supplemented with 60 µM 6-thioguanine (6-TG). 4T1 cells were 
cultured in standard cell culture medium without 6-TG. 4T1-derived cell lines from primary tumors, 
CTCs, DTCs, and metastases were initially selected in 6-TG-containing medium and thereafter 
maintained in standard culture medium.  
2.2.1.2 Cell passaging  
Cells were washed twice by using each 10 mL of PBS buffer after removal of the cell culture medium. 
Then, 3 mL trypsin solution was added to let cells detach from the culture flask. After a 3 to 20 min 
incubation in trypsin solution, trypsin was neutralized by mixing with 3 times the volume of culture 
medium containing FBS. The cell suspension was split as required and varying in ratio from 1:6 to 
1:10.  
Several DTC1-derived CTC lines grew in a semi-adherent way. Therefore, cell culture medium from 
these cell lines was collected and centrifuged for collecting cell pellets of poorly adherent cells. 
Thereafter, poorly adherent cells were suspended in 3 mL of trypsin solution and were put back to 
flask. Then, poorly adherent cells together with adherent cells were split as mentioned above. 
All cell lines were cultured in an incubator at a 5 % CO2 atmosphere at 37 ℃. 
2.2.2 Flow cytometry 
In the present study, flow cytometry was applied for testing the expression of transmembrane proteins 
(EpCAM and CD45) at the cell surface. 
General procedure: Cells were collected and washed two times in FACS buffer (PBS containing 3% 
FBS). Cells were suspended in 50 μL FACS buffer, next mixed with 1 μL EpCAM- or CD45-specific 
antibody and incubated for 15 min. After centrifuging and washing twice in 500 μL FACS buffer, cells 
were suspended in 50 μL FACS buffer and incubated with 1 μL fluorescein isothiocyanate (FITC)-
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conjugated secondary antibody for 15 min. Then, cells were washed twice before resuspending in 500 
μL FACS buffer with propidium iodide (PI, 1 mg/mL). Finally, the cell suspension was analyzed in a 
FACS Calibur cytometer to measure the expression of EpCAM or CD45. The control group was 
performed using a secondary antibody only. 
2.2.3 Proliferation assay 
Cells were harvested from growing cultures at a confluency of 50 - 80 %. Cell numbers were measured 
by a trypan blue exclusion assay. To do so, an aliquot of 10 μL of cell suspension was taken from each 
cell sample and mixed with 10 μL trypan blue solution (0.4%), from which 10 μL were counted in a 
Neubauer chamber. Finally, 5,000 cells were seeded per well in a 6-well plate format in n = 10 repeats 
for each experimental cell line. Cell numbers were counted from day 1 to day 5 in duplicates for each 
day. For semi-adherent cell lines, the used media were collected and centrifuged to include non-
adherent cells. 
2.2.4 Cell metabolism 
To assess the metabolic activity of cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was used. MTT is a yellow tetrazole, which can be metabolized to purple 
formazan ad in living cells (Stockert et al., 2018). Initially, the trypan blue assay was used to obtain 
absolute cell numbers, and 1,000 cells were plated in triplicates in 3 × wells of 96-well plates per cell 
line. On day 1, day 3, and day 5, MTT solution (5 mg/mL) was mixed with cells to reach a 
concentration of 0.5 mg/mL, was incubated for 4 h at 37 ˚C, and thereafter 200 μL MTT solvent (0.1 
N HCl in isopropanol) were added to dissolve formazan crystals. The dissolved purple formazan was 
measured in a microplate reader at an optical density (OD) of 570 nm wavelength and 690 nm (as a 
reference) (Mosmann, 1983). 
2.2.5 Single cell deposition for single cell-derived clones 
Cell numbers of 4T1, CTC1, and DTC1 were measured by trypan blue exclusion assay. Thereafter, 
cell suspensions were diluted to 150 cells in 30 mL of culture medium. Cell suspensions were seeded 
in 96-well plates in a volume of 100 μL/well, corresponding to 0.5 cell/well. After 7 - 10 days, cell 
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colonies were observed under a microscope. Colonies growing to high confluence were transferred 
independently to 6-well plates and further expanded in culture flask. 
2.2.6 Transwell invasion assay 
The transwell invasion assay was conducted with Matrigel-coated transwell inserts. To prepare the gel 
layer, 200 μL of 0.9 mg/mL Matrigel in DMEM was coated on 24-well plate inserts with 8 μm pores. 
Cell numbers were assessed and 1×105 cells were seeded in 200 μL serum-free DMEM into the upper 
chamber. The lower chamber of the invasion chamber was filled with 800 μL standard cell culture 
medium containing 10% FBS. Thereafter, cells were incubated at 37 °C for 16 h to allow migration 
and invasion. Following this incubation, cells on the surface of the upper chamber were flushed and 
washed with PBS. Next, migrated cells on the insert membrane were fixed and stained with 1 % crystal 
violet/ 70 % methanol solution for 20 min. Afterwards, insert membranes were washed twice in PBS 
and air dried. Pictures of the stained inserts were taken before membranes were transferred to 96-well 
plates. Thereafter, 200 μL acetic acid were added to dissolve crystal violet-stained cells. The OD at 
590 nm was assessed in a microplate reader. 
2.2.7 Adhesion assay 
Calcein-AM is a fluorescent dye, which can be used for the short-term labeling of living cells. The 
fluorescence intensity of Calcein-AM is proportional to the amount of living cells. To prepare the 
bottom layer, 96-well plates with flat bottom were coated with 50 μL of Gelatin (0.2 % in PBS), 
Matrigel (100 μL/mL in PBS), or were left uncoated. Cells were harvested and 5×105 cells were 
incubated with Calcein-AM (10 μM) for 30 min at 37 °C. Thereafter, cells were washed three times 
with PBS and suspended in 1 mL culture medium. Next, 2.5×104 labeled cells in 50 μL culture medium 
were seeded in triplicates in 96-wells with Gelatin, Matrigel, or no coating, and incubated in the dark 
for 2 h at 37 °C for cell-matrix adhesion. Next, media were removed and 96-well plates were carefully 
washed twice with PBS. Adherent cells were lysed by adding 100 μL Triton X-100 (2 % in distilled 
water). In the input control wells, cells were directly lysed by adding 1 μL Triton X-100 solution 
without removing media. The Calcein-AM fluorescence was measured in a Victor Wallac instrument.  
MATERIALS AND METHODS 
25 
 
2.2.8 Endothelial adhesion assay 
To prepare the endothelial cell monolayer, 1×105 murine endothelial bEnd.3 cells in 100 μL of culture 
medium were plated in 96-well plates and cultured for 24 - 48 h to form an endothelial cell layer. 
Before the addition of tumor cells, endothelial cells were activated by adding TNF-α (10 ng/mL) for 5 
h. After the removal of the old medium containing TNF-α, 2.5×104 Calcein-AM-labeled cells in 50 
μL medium were plated per well and incubated for 2h to allow cells to adhere. Further measurements 
of adherent cells were performed as described in the adhesion assay protocol (Paragraph 2.2.7). 
2.2.9 Chemoresistance assay 
In order to test for chemoresistance, cells were cultured in medium with Doxorubicin or Cisplatin, and 
MTT assay was conducted to measure the cell viability after defined time periods. Briefly, 5,000 
cells/well were seeded 8 times in triplicates in 96-well plates and incubated for 24 h. Next, cells were 
cultured in 100 μL medium containing 120, 60, 30, 15, 7.5, 3.75, or 1.875 μM Doxorubicin or Cisplatin 
for 48 h, and the control group was kept untreated. After treatment with chemotherapeutic agents, MTT 
solution was added to reach a final concentration of 0.5 mg/mL and incubated with cells for 4 h at 37 
˚C. Then, the MTT solvent was added. The OD at 570 nm wavelength and 690 nm (as a reference) 
was measured in a microplate reader. Cell viability curves were calculated at different treatment 
concentrations. The IC50 (the drug concentration that can induce 50 % death of treated cells) value was 
calculated by using GraphPad Prism 5. Cell viability was calculated according to the following 
equation: 
Cell viability = 
mean(OD of treated cells −OD of blank)
mean(OD of control −OD of blank)
. 
2.2.10 2D colony formation assay 
Cell numbers were assessed by trypan blue assay and diluted to lower concentration (≤ 1×104 cells 
/mL). Thereafter, 50, 100, and 200 cells were suspended in 10 mL culture medium and plated in culture 
dishes (diameter of 10 cm). After incubation for 11 days, media were removed, and dishes were washed 
twice with PBS. Colonies were stained with 1 % crystal violet/70 % methanol solution for 20 min. 
Then, plates were washed with PBS twice and air-dried. Numbers of colonies were counted manually, 
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where clusters containing ≥ 30 cells were defined as a cell colony. The sizes of colonies were assessed 
by image J software. Plating efficiency was calculated by the following equation:  
Plating efficiency = no. of colonies formed / no. of cells seeded x 100%.  
2.2.11 3D soft agar colony formation assay 
Firstly, 5 % and 3.5 % low melting point (LMP) agarose (weight (g)/volume (mL)) solution were 
prepared by dissolving 5 g or 3.5 g LMP agarose in 100 mL PBS, followed by autoclaving for 2 h. 
Before the experiment, the agarose solution was liquefied by heating and kept in a 40 °C water bath. 
The agarose bottom layer was generated by mixing 1 mL of 5 % agarose with 9 mL culture medium 
to reach a final concentration of 0.5 % agarose/medium solution. The 0.5 % agarose/medium solutions 
were quickly plated into culture dishes and solidified at room temperature for 30 min. Afterwards, 1×
104 cells were resuspended in 9 mL of culture medium and quickly mixed well with 1 mL 3.5 % LMP 
agarose, then plated into 0.5 % agarose/medium solution coated plates. After 7 days, colony numbers 
were observed and counted under a microscope. Cell clusters containing more than 30 cells were 
considered as a colony. The sizes of the colonies were calculated by Image J software.  
2.2.12 mRNA isolation 
The RNeasy Kit containing QiaShredder columns was applied to isolate mRNA from cells according 
to the manufacturer’s protocol (http://www.bea.ki.se/documents/EN-RNeasy%20handbook.pdf). 
Briefly, cells were harvested and lysed in RLT buffer (supplied in the RNeasy Kit). To homogenize 
the lysate, the cell lysate was pipetted to a QIAshredder spin column, put in a 2 mL tube (supplied in 
the RNeasy Kit), and centrifuged for 2 min at high speed (> 8,000g). Then, 1 volume of 70 % ethanol 
was added to the homogenized lysate and were mixed thoroughly. Afterwards, 700 μL of the sample 
were added to an RNeasy spin column and were put in a 2 mL tube. After centrifugation for 15 sec at 
≥ 8,000 g, the flow-through was discarded. Next, 700 μL of RW1 solution were added to the RNeasy 
spin column and centrifuge for 15 sec at ≥ 8,000 g. The flow-through was discarded. To wash the spin 
column membrane, 500 μL of RPE buffer were added and centrifuged for 15 sec at ≥ 8,000 g. This 
washing step was repeated twice. Then, the RNeasy spin column was put in a new 1.5 mL RNase-free 
tube. To elute RNA, 30 - 50 μL RNase-free water was added into the spin column membrane. After 
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incubating for 2 min, the RNeasy spin column was centrifuged for 1 min at ≥ 8,000 g. The flow-
through contained the extracted mRNA and was stored at -20°C for further use. 
2.2.13 Reverse transcription polymerase chain reaction (RT-PCR) 
Extracted mRNA was first reverse transcribed to cDNA, and cDNA was applied for qRT-PCR 
measurements to test gene expression levels. The QuantiTect® Reverse Transcription kit was used for 
reverse transcription. The reaction process was conducted following the manufacturer’s protocol 
(QuantiTect® Reverse Transcription Handbook - Qiagen). First, the concentration of mRNA sample 
was measured a GeneQuantPro spectrophotometer and 1 μg mRNA was used to prepare the Reaction 
Mix 1 (table below). The Reaction Mix 1 was incubated for 2 min at 42°C, then immediately put on 
ice.  
Reaction Mix 1 (Genomic DNA elimination reaction components): 
 
 
 
 
 
 
Next, the Reaction Mix 1 was used to prepare the Reaction Mix 2 according to the table below, and 
was incubated for 20 - 30 min at 42°C. 
Reaction Mix 2 (Reverse-transcription reaction components): 
Component Volume/reaction Final concentration 
Quantiscript reverse 
transcriptase 
1 μL  
Quantiscript RT Buffer, 5x 4 μL 1x 
RT Primer Mix 1 μL  
Component Volume/reaction Final concentration 
gDNA Wipeout buffer, 7x 2 μL 1x 
Template RNA 1μg  
RNase-free water Variable  
Total volume 14 μL - 
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Template RNA 
(Reaction Mix 1) 
14 μL  
Total volume 20 μL – 
To inactivate the Quantiscript reverse transcriptase, the Reaction Mix 2 was incubated for 3 min at 
95°C, then immediately put on ice. Afterwards, 20 μL cDNA samples were diluted 1:10 with 180 μL 
ddH2O and short-term stored at -20 °C. 
2.2.14 Quantitative Real-Time PCR (qRT-PCR) 
cDNA samples were applied for qRT-PCR to study the expression of genes of interest. SYBR Green 
PCR Master Mix kit was used to quantify gene expression. 
 Standard master-mix (per reaction) was prepared as below: 
 
 
 
 
 
 
 
 
Primer mix: a mix of forward and backward primers for each gene of interest (each primer 1 μL corresponding to 5 μM). 
 
 Gene expression was tested in the Light Cycler 480 System (Roche, Mannheim, Germany). The 
reaction setup was as below
Component Volume/reaction 
cDNA template 1 μL 
Primer mix 2 μL 
SYBR Green master-mix (2x) 5 μL 
ddH2O 2 μL 
Total 10 μL 
Procedure Time Temperature 
Initial denaturation 10 min, 95°C 
Denaturation 30 sec 95°C 
Annealing and elongation   
 45 repeats 
60 sec 
72°C  
back to denaturation step 
Cooling/Storage ∞ 4°C 
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Gene expression level of glucuronidase-beta (Gusb) was used as a reference. Gene expression levels 
were calculated according to the equation 2-ΔΔCT; 
ΔCT = CTgene of interest - CTendogenous control  
ΔΔCT = ΔCTgene of interest - ΔCTreference   
ΔCT values were used for statistical comparison. 
2.2.15 Animal experiments 
2.2.15.1 Ethical statements 
Mouse experiments were approved by the local Ethical Committee-Regierung von Oberbayern, 
Munich, Germany (Az 55.2.1.54-2532-90/12 and 177/15) at the laboratory of PD Dr. Sebastian Kobold, 
Division of Clinical Pharmacology, Ludwig-Maximilians-University, Munich, Germany. 
2.2.15.2 Tumorigenicity assay 
Experimental animals (female BALB/c mice) were generally between 6 - 8 weeks old. Cells numbers 
for transplantations were calculated by trypan blue assay, then 1.25×106 cells were suspended in 1 mL 
of PBS. Cell suspensions were stored a short time on ice. Then, 100 μL PBS/cell suspension (1.25×
105 cells) were subcutaneously injected into the flank of the mice. The sizes of the tumors were 
assessed every 2 - 3 days. Mice were sacrificed after 27 days. To do so, mice were anesthetized by 
inhaling 0.4 % isofluorane, then blood was collected from the orbital sinus, and femurs and tibiae were 
collected. Primary tumors were weighted. Primary tumors and organs, including lung, spleen, kidney, 
and liver, were collected in order to cryopreserve samples for IHC staining and to establish ex vivo 
sublines. 
In the second round of mouse experiment, 1.25×106 4T1 and DTC1 cells, and 5×106, 1×107, and 2×
107 CTC1 cells were resuspended in 1 mL PBS. Then, 100 μL of cells in PBS were subcutaneously 
transplanted into the flank of BALB/c mice. Tumor size was measured every 1 - 2 days. After 15 days, 
mice were sacrificed, primary tumors were weighted. Lungs were harvested and a short time kept in 
culture medium on ice to further perform a metastatic colony formation assay.  
MATERIALS AND METHODS 
30 
 
2.2.15.3 Ex vivo establishment of CTCs lines 
To establish stable CTC lines ex vivo, blood was collected from BALB/c mice at the end of the 
tumorigenicity experiments. Blood volumes varied between 0.8 mL and 1 mL per mouse. Blood was 
collected in heparin covered sterile tubes and stored for short time on ice. Blood samples were first 
eliminated RBCs by adding ammonium chloride-based lysis reagent. After 2 min incubation time, cells 
were centrifuged and washed twice with PBS. Next, cell pellets (containing white blood cells and 
potential CTCs) were resuspended in 10 mL selection medium containing 60 μM 6-TG, and were 
plated in 2-fold serial dilutions in 96-well plates with a starting volume of 100 μL. Cell colonies were 
observed under a microscope and were expanded individually to 12-well plates and later to 6-well 
plates. Finally, selected cells were established as ex vivo CTC lines. 
2.2.15.4 Ex vivo establishment of DTCs lines 
To establish DTC lines ex vivo, mice were sacrificed, and femurs and tibiae were collected. After 
removing skin and muscles, the joints of hips and knees were cut out from femurs and tibiae, and bone 
marrows were flushed out with PBS by using a syringe. The flushed-out cells were centrifuged and 
supplemented with 10 mL of ammonium chloride-based lysing reagent to deplete the cell suspension 
of RBCs. After washing with PBS, cell pellets were resuspended in 10 mL selection medium 
containing 60 μM of 6-TG, and cell lines were generated as described in the previous paragraph for 
CTCs. 
2.2.15.5 Ex vivo establishment of primary tumor and metastasis cell lines 
To establish tumors and metastases cell lines ex vivo, primary tumors and organs (lung, spleen, kidney 
and liver) were collected and short-time stored in tubes with culture medium on ice. Primary tumors 
and organs were cut into small pieces in 10 cm2 dishes, then minced through a 100 μm filter. After 
washing twice with PBS and centrifuging, cell pellets containing tissue cells and tumor cells were 
suspended in 10 mL selection medium. Each tumor or organ cell suspension was plated independently 
in a 10 cm2 culture dish. Growing cells were observed under a microscope. When selected cells grew 
to confluence, they were transferred to flasks for further maintenance. 
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For all established cell lines in vitro, passage numbers less than 5 were used for re-injection in vivo, 
and passage numbers below 10 were used for performing functional assays. 
2.2.15.6 Intravenous (i.v) injection and lung metastasis formation 
To study the capability of tumor cells to form lung metastasis, cells were intravenously injected in 
BALB/c mice (age-matched 6 - 8 weeks) through the tail vein. Brief procedure: cells numbers were 
assessed by trypan blue assay, then 5×105 cells were suspended in 1 mL of PBS. 100 μL of cells in 
PBS (5×104 cells) were injected into the tail vein. Mice were observed every 1 - 2 days and sacrificed 
at day 19. Superficial metastatic nodules in the lungs were assessed by visual inspection and lungs 
were harvested to further perform a metastasis colony formation assay. Alternatively, 5×104 cells in 
100 μL of PBS were injected into the tail vein of BALB/c mice. After injection, mice were checked 
daily for signs of endpoints to the experiment in each group. The defined endpoints were: (1) 
substantial weight loss (more than 5% in more than two mice out of five), (2) weakness, i.e. tiredness 
and unresponsiveness (more than 2 mice out of five), (3) ≤ 2 remaining experimental groups. Mice 
weights were measured every 1 - 2 days to calculate weight-curves. For each group, mice were 
anesthetized before being sacrificed, and autopsy was performed to study the metastatic status of each 
mouse. Metastatic nodules in lungs were assessed by visual inspection and lungs were collected for 
metastasis colony formation assay. 
2.2.15.7 Metastasis colony formation assay 
To quantify lung metastases, the metastasis colony formation assay was conducted. Entire lungs were 
collected after autopsy, and were cut into small pieces and incubated in RPMI medium containing 
collagenase (5 mg/mL) and DNase (1 mg/mL) for 30 min. Next, lung fragments were minced through 
a 100 μm filter. Cells remaining in the filter were rinsed with 5 mL of PBS. Tissue fragments were 
further minced through a 40 μm filter and rinsed with 5 mL of PBS. Cell suspensions were centrifuged 
and cell pellets were incubated with ammonium chloride-based lysing reagent for 2 min to deplete the 
cell suspension of RBCs. After centrifugation and washing, cells were suspended in 10 mL of selection 
medium (60 μM 6-TG), and 1 mL of cells was taken to dilute to 1:100 in selection medium. 
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Sequentially, 3 mL of each concentration were seeded in 6-well plates in triplicates. After 10 days for 
subcutaneous and after 4 days for i.v transplantation of tumor cells, metastatic colonies were stained 
with 1% crystal violet/70 % methanol solution for 20 min. Then, plates were washed with PBS twice 
and air dried. Numbers of colonies were counted manually, where clusters containing more than 20 
cells were considered as a colony. 
2.2.15.8 Immunocytochemistry and immunohistochemistry staining 
Sample preparation: to perform immunohistochemistry staining, tumors or organs were collected and 
preserved in cryomolds. Then, tissues were covered with Tissue Tek gel avoiding the formation of air 
bubbles, and carefully frozen in liquid nitrogen. Frozen tissue samples were cut to serial sections of 3 
- 5 μm thickness and mounted on glass slides. For immunocytochemistry, cells were seeded on glass 
slices, covered with culture medium, and incubated overnight to allow cells to adhere. Immunostaining 
was done by our technician Gisela Kranz and was conducted according to the avidin-biotin-peroxidase 
method (Vectastain, Vector laboratories, Burlingame, CA, USA) 
(https://docs.abcam.com/pdf/protocols/ihc-immunostaining.pdf). Briefly, the sample slides were 
gently washed twice for 5 min in Tris-Buffered Saline (TBS) plus 0.025% Triton X-100 to reduce 
surface tension. Then, samples were blocked in 10% normal serum with 1% Bovine Serum Albumin 
(BSA) in TBS for 2 h. Slides were air-dried for several seconds and tissue paper was used to wipe 
away excess of TBS buffer. Primary antibodies (EpCAM, E-Cadherin, Vimentin, Cytokeratin) were 
diluted in TBS with 1% BSA (concentrations depend on manufacturer’s recommendations, normally, 
0.5 - 10 μg/mL) and incubated with sample slides overnight at 4°C. Afterward, slides were rinsed twice 
for 5 min in TBS with 0.025% Triton. The secondary antibody was diluted in TBS with 1% BSA 
(concentrations depend on manufacturer’s recommendations, normally, 0.5 - 5 μg/mL) and was 
incubated with sample slides for 1 h at room temperature. After staining with chromogen for 10 min, 
slides were rinsed in tap water for 5 min. After dehydration, clear and mount process, slides could be 
observed under the microscope. 
Immunohistochemistry intensity scores (IHC scores) were calculated as the product of protein 
expression intensity (0 to 3; 0, negative; 1, weak; 2, moderate; 3, strong) and the percentage of 
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expressing cells per area (score 0 = 0 ~ 5 %, 1 = 5 ~ 25 %, 2 = 25 ~ 50 %, 3 = 50 ~ 75%, 4 = 75 ~ 
100 %).  
2.2.15.9 EMT scoring 
EMT score was applied to compare the level of mesenchymal transition of cells. It was defined as the 
product of the percentage of mesenchymal-, spindle-like cells (0 - 100%) and the level of cell-cell 
contact (disseminated cells represent 0 ~ 25% - 1, 25 ~ 50% - 2, 50 ~ 75% - 3, 75 ~ 100% - 4). Thereby, 
an EMT score of 0 represents cells in a highly epithelial state, whereas a score of 400 represents 
strongly mesenchymal cells.2.2.16 Clinical study 
The clinical study was performed in cooperation with the laboratory of Prof. Hongxia Wang, 
Department of Oncology, Shanghai General Hospital, Shanghai, China. The clinical study was 
approved by the Ethics Committee of Shanghai General Hospital (ethics #2018KY153). The clinical 
study was conducted obeying the Declaration of Helsinki Principles. 
2.2.16.1 Clinical cohort 
Breast cancer patients, who were at tumor stage III - IV and received inpatient treatment, were included 
in the clinical study with informed written consent. From September 2015 to April 2017, 34 metastatic 
breast cancer patients were enrolled at Shanghai General Hospital. Patients’ information was 
anonymized and de-identified prior to analysis. Patients were followed from September 2015 to 
January 2018. 
2.2.16.2 Subtraction enrichment of CTC and DTC 
Enrichment of CTC and DTC was conducted following the manufacturers’ instructions (Cytelligen, 
San Diego, CA, USA) (Lin et al., 2017) at Shanghai General Hospital by our cooperation partner Dr. 
Junjiang Li. Blood and bone marrow samples were collected before patients received any treatment. 
To avoid contamination of epithelial cells, the first 2 mL of blood or bone marrow sample were 
discarded. For each patient, 6 mL of blood and 3 mL of bone marrow samples were collected at the 
same time. Blood and bone marrow samples were first centrifuged at 600 g for 5 min. Cell pellets 
were depleted RBC by going through a non-hematopoietic cell separation matrix. Then, the 
remaining cells were incubated with anti-WBC immunomagnetic beads. After centrifugation at 400 g 
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for 5 min, supernatants were collected. The supernatants containing rare cells were centrifuged at 
500 g for 2 min. Cell pellets were carefully collected and fixed in CTC slides (Cytelligen) for further 
staining. 
2.2.16.3 Identification of CTC and DTC by SE-iFISH 
The experiment was conducted at Shanghai General Hospital by our cooperation partner Dr. Junjiang 
Li and Dr. Peter Lin from Cytelligen (San Diego, USA). Centromere Probe (CEP8), anti-CD45, anti-
EpCAM antibodies were used for cell staining. Cell nuclei were stained with DAPI. CTCs and DTCs 
were defined as cells with a DAPI-positive nucleus, a lack of CD45 expression, heteroploidy at 
chromosome 8, with or without EpCAM expression, or diploid CEP8 signals with EpCAM expression. 
Cell clusters were defined as visualizing more than two cells in cell-cell contact. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
35 
 
2.3 Statistical analysis 
Statistical analysis was performed by computer software, including Prism5, Microsoft Excel, and 
SPSS. The Kolmogorov–Smirnov test was used to define whether data sets obeyed normal 
distribution. If data sets had a normal distribution, unpaired or paired t-test was used for comparing 
between unpaired or paired two groups, one-way ANOVA and post hoc Bonferroni t-test for multiple 
comparisons. If data sets did not obey a normal distribution, Mann–Whitney U test was used to 
compare the difference between two independent groups, the Wilcoxon signed-rank test was used to 
compare two related samples, and Kruskal-Wallis test with post hoc Dunn ś test was applied for 
comparing multiple groups. The correlation between EMT score and EpCAM expression was 
analyzed by Spearman’s rank test. Receiver operating characteristic (ROC) curves assessed the 
capability of the EpCAM-positivity rate of cells to predict patients’ outcomes. Patients’ overall 
survival was analyzed by the Kaplan–Meier curve. Results were shown as mean values ± standard 
deviation (SD.) from at least three independent experiments. P-values < 0.05 were considered 
significant. 
Statistics shown in figures within this thesis are: ns: not significant, * < 0.05, ** < 0.01, *** < 0.001. 
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3. RESULTS 
In this study, the aim was to analyze the contribution(s) of an EMT to the metastatic potential of MBC 
cells. To do so, a syngeneic mouse model of MBC was used to recapitulate all stages of the cancer 
progression, from the formation of primary tumors to the growth of distant metastases in the lungs. 
3.1 The 4T1 MBC mouse model 
4T1 cells are transplantable murine breast cancer cells that were first generated by Fred Miller and 
colleagues (Miller et al., 1981; Miller et al., 1987). After syngeneic transplantation into 
immunocompetent BALB/c mice, 4T1 cells form primary tumors and induce distant metastases at 
multiple sites (i.e. lung, liver, kidney, bones). 4T1 cells have been selected for their resistance to 6-TG, 
a guanine analogue that inhibits the syntheses of DNA and RNA, and thus, eventually causes cell death. 
This inherent property of 4T1 cells to proliferate in the presence of 6-TG allows for the ex vivo isolation 
of 4T1-derived tumor cells by selecting cells in medium supplemented with 6-TG. In order to establish 
ex vivo cultures of CTC and DTC lines, 4T1 cells were subcutaneously transplanted to the flank of 
BALB/c mice (age-matched between 6 - 8 weeks old). After 3 - 4 weeks, with the generation of the 
primary tumors, mice were sacrificed, and blood, bones, and organs were collected for selections of 
CTC, DTC, and metastasis-derived cell lines (Figure 1).  
Figure 1: Scheme of the 4T1 mouse model: 4T1 cells were subcutaneously transplanted in the flank of BALB/c mice. 
After 3 - 4 weeks, mice were sacrificed, blood, bone, primary tumors, and organs were harvested for the isolation of 4T1-
derived sublines from each localization. 
 
In the first round of animal experiments, n = 5 BALB/c mice were transplanted with 4T1 cells. All 
mice developed primary tumors, and, hence, blood and bones were used for the isolation of CTCs and 
DTCs. As a result, one CTC line and one DTC cell line were successfully generated as ex vivo cultures 
from blood and bone marrow, namely CTC1 and DTC1, respectively (Figure 2). The culture procedure 
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was described in detail in the Methods section 2.2.15. CTC1 and DTC1 cells grew in an adherent 
manner and an obvious difference of EMT phenotypes was observed between 4T1, CTC1, and DTC1 
cells. Parental 4T1 cells show a classical epithelial phenotype with a cobblestone-like morphology and 
tight cell-cell junctions (Epithelial, E-type), whereas CTC1 cells displayed a typical mesenchymal 
phenotype, in which cells are spindle-shaped and have lost cell-cell contact (Mesenchymal, M-type). 
DTC1 cells showed a partial EMT compared to 4T1 cells, and hence the phenotype of DTC1 cells was 
defined as an E/m-type, reflecting that cells have gone through a restricted EMT and still maintained 
a major epithelial type. 
Figure 2: EMT phenotypes of 4T1, CTC1, and DTC1 cells in vitro. Hematoxylin and eosin staining of 4T1, CTC1, and 
DTC1 cells. Shown are representative photographs of the morphology of each cell line grown under standard cell culture 
conditions. Scale bars are indicated in each picture. 
 
To assess a potential contamination of the generated cell lines with white blood cells, the leukocyte 
marker CD45 was measured by flow cytometry in 4T1 cells (as a negative control), CTC1, and DTC1 
cells (Figure 3). The result confirmed that CD45 was not expressed in any of these three cell lines. 
Figure 3: CD45 expression in 4T1, CTC1, and DTC1 cells was tested by flow cytometry. Shown are representative 
histograms of CD45 expression in each cell line from n = 3 independent experiments. CD45 antibodies (black) and isotype 
controls (grey). 
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Morphological changes in CTC1 and DTC1 cells could be caused by culture condition, e.g. long-term 
6-TG treatment might have an influence on 4T1 cell morphology. To test this eventuality, 4T1 cells 
were cultured in medium containing 6-TG for 28 days and the morphology of the cells was recorded 
every 7 days as micrographs. The result demonstrated that 6-TG per se did not induce an EMT in 4T1 
cells (Figure 4). 
Figure 4: 6-TG treatment of 4T1 cells. 4T1 cells were cultured in medium containing 6-TG for 28 days and cell 
morphology was assessed at the indicated time points. Representative pictures taken at each indicated time point are showed. 
 
EMT is usually accompanied by switching the expression of EMT-related genes. Therefore, 
immunocytochemistry staining was conducted to study the expression of epithelial and mesenchymal 
markers. Figure 5 shows that 4T1, CTC1, and DTC1 cells expressed substantial amounts of epithelial 
marker Cytokeratin and mesenchymal marker Vimentin. In addition, the epithelial markers EpCAM 
and E-cadherin were highly expressed in 4T1 and DTC1 cells, but were entirely lacking in CTC1 cells. 
Figure 5: Immunocytochemistry staining of EpCAM, E-cadherin, Cytokeratin, and Vimentin in 4T1, CTC1, and DTC1 
cell lines. Representative pictures from n = 3 independent experiments are shown with scale bars. 
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EpCAM is an epithelial marker that is widely applied for the isolation and detection of CTCs. We 
tested the cell surface expression of EpCAM among 4T1, CTC1, and DTC1 cells by flow cytometry. 
Parental 4T1 cells expressed EpCAM to a high level, while EpCAM was entirely negative in CTC1 
cells, and DTC1 contained a mix of EpCAMhigh cells, EpCAMintermediate cells, and a small proportion 
of EpCAMnegative cells (Figure 6). Interestingly, two distinct populations of EpCAM-positive cells with 
differing expression levels could be visualized as high and intermediate in DTC1 cells. This result 
confirmed the findings of the immunocytochemistry staining of EpCAM. 
Figure 6: Flow cytometry analysis of EpCAM expression in 4T1, CTC, and DTC1 cells. The left panels show 
representative histograms of EpCAM expression (EpCAM in black, controls in grey). Quantification of EpCAM expression 
on 4T1, CTC1, and DTC1 cell lines are shown as means ± SD from n ≥ 5 independent experiments in the right panel. 
 
Next, mRNA levels of epithelial markers EpCAM, E-cadherin, Rab25, Ddr1, Grhl2, and Krt19, and 
of mesenchymal markers N-cadherin, Vimentin, Slug, Zeb1/2, Erbb2/3, Snail, and Twist were 
measured in 4T1, CTC1, and DTC1 cells by quantitative RT-PCR. As shown in Figure 7, a significant 
reduction of the expression of epithelial markers EpCAM, E-cadherin, Rab25, and Grhl2 and an 
increase of the expression of mesenchymal markers N-cadherin, Vimentin, Slug, ZEB1, ZEB2 was 
measured in CTC1 cells. Furthermore, no significant difference was found for the expression of Ddr1, 
ErbB2, ErbB3 between 4T1, CTC1, and DTC1 cells (Figure 7). Krt19 was unexpectedly highly 
expressed, and EMT-TF Snail and Twist were expressed to lower levels in CTC1 and DTC1 cells 
compared to 4T1 cells (Figure 7).  
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Figure 7: mRNA expression levels of epithelial and EMT markers in 4T1, CTC1, and DTC1 cells. mRNA expression 
levels of the indicated genes were assessed by qRT-PCR in 4T1, CTC1, and DTC1 cells. Gene expression of Gusp was 
applied as a reference to normalize all samples. Bar charts show results with means ± SD from n = 3 independent 
experiments. Normalized gene expression of 4T1 cells was set to 1 as reference. 
 
3.2 EMT in CTC1 cells is accompanied by increased migration, but reduced 
proliferation and tumor formation ability 
To understand the influence of EMT on the behaviour and functional capacities of tumor cells, in vitro 
functional assays and in vivo tumorigenic studies were conducted. First, proliferation and cell 
metabolism were analyzed by cell counting and MTT assay, respectively. Results from the MTT assay 
demonstrated that 4T1 cells represented the highest cell metabolism, followed by DTC1 and CTC1 
cells (Figure 8A). Cell numbers were assessed by cell counting over a total time period of 5 days. 
Results of cell counting were similar to the cell metabolism assay, where 4T1 had the highest cell 
numbers and CTC1 had the lowest cell counts, while DTC1 cells showed an intermediate cell count 
(Figure 8B). 
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Figure 8: Comparison of cell metabolism and proliferation between 4T1, CTC1, and DTC1 cells. (A) Cell metabolism of 
4T1, CTC1, DTC1 cells was measured by MTT assay (initial seeding number, 1,000 cells). (B) The proliferation of 4T1, 
CTC1, DTC1 was tested by cell counting (initial seeding number, 5,000 cells). Line charts show means ± SD from n ≥ 3 
independent experiments. 
 
The two-dimensional (2D) colony formation assay essentially assesses every single cell for its capacity 
to undergo “unlimited” division. The three-dimensional (3D) colony formation assay or soft agar 
colony formation assay tests the cells’ ability to grow in an anchorage-independent condition. In 2D 
colony formation assays, 4T1, CTC1, and DTC1 cells had a similar capacity in anchorage-dependent 
“unlimited” cell growth (Figure 9). When observing the cell colonies under the microscope, the 
morphology of colonies showed substantial differences among these cell lines. CTC1 cells formed the 
biggest cell colonies with loose cell-cell contact, while 4T1 cells generated the smallest colonies with 
tight cell-cell connections. DTC1 cells showed intermediate colony size and relatively loose cell-cell 
connection compared to 4T1 cells. To compare the size of cell colonies, pictures were taken and the 
size of colonies was assessed by the Image J software. The results confirmed that the average colony 
size of CTC1 cells was 11.07 ± 2.68 mm2 and it was the highest among these cell lines, followed by 
DTC1 cells (7.17 ± 3.16 mm2) and 4T1 cells (5.45 ± 2.09 mm2) (Figure 9, upper right panel). The 
colony size of CTC1 cells was significantly larger than the parental 4T1 cells, while no significant 
difference was observed compared to DTC1 cells (Figure 9, upper right panel). 
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Figure 9: 2D colony formation capacity of 4T1, CTC1, and DTC1 cells. Upper left panel: Shown is the plating efficiency 
of 4T1, CTC1, and DTC1 cells from n = 4 independent experiments in box-plot whiskers graphs with means ± SD. Upper 
right panel: Shown is the colony size as calculated using the Image J software. Box-plot whiskers graphs show means ± 
SD from n = 4 independent experiments. Lower panels: Shown are representative images of 2D colony edges and crystal 
violet-stained colonies from 4T1, CTC1, and DTC1 cells (initial seeding number of 200 cells) from n = 4 independent 
experiments.  
 
In the 3D colony formation assay, CTC1 cells showed highest ability in anchorage-independent cell 
growth (Figure 10A). To compare the size of 3D-colonies, 12 colonies per cell line were randomly 
chosen and the size of area for each colony was measured by the Image J software. The result reflected 
that 4T1 cells formed the smallest 3D colonies with clearly defined edges. CTC1 cells generated the 
largest colonies with loose edges, while DTC1 cells generated intermediately sized colonies and their 
colony edges had both sharply and loosely defined areas (Figure 10B). 
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Figure 10: 3D colony formation capacity of 4T1, CTC1, and DTC1 cells. (A) Box-plot whiskers graphs show numbers of 
colonies from 4T1, CTC1, and DTC1 cells as means ±  SD from n = 4 independent experiment. (B) Shown are 
representative images of colonies from 4T1, CTC1, and DTC1 cells (left), and quantification of 3D colony size in dot plots 
(right) from n = 12 randomly selected colonies. 
 
Adhesion is an important trait of tumor cells in order to intravasation and extravasation from blood 
vessels. To test the adhesion of 4T1, CTC1, and DTC1 cells, an adhesion assay was performed. Murine 
endothelial cells (bEnd.3), Matrigel, and Gelatin were used as adhesion matrix. The result 
demonstrated that in comparison with 4T1 and DTC1 cells, CTC1 cells were characterized by 
significantly reduced adhesion to Matrigel and Gelatin (Figure 11). In addition, DTC1 cells showed 
the highest adhesion to endothelial cells, 1.38-fold higher than 4T1 and 2.01-fold higher than CTC1 
cells (Figure 11). 
Figure 11: Adhesion of 4T1, CTC1, and DTC1 cells to bEnd.3 endothelial cells, Matrigel, and Gelatin. Shown are means 
± SD adhesion rates of 4T1, CTC1, and DTC1 cells from n ≥ 3 independent experiments. 
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Invasion is an important characteristic of tumor cells that is critical for the process of metastasis 
formation. A Boyden chamber invasion assay with Matrigel-coated inlays was performed to measure 
the migration ability of 4T1, CTC1, and DTC1 cells. The result of the invasion assay showed that 
CTC1 and DTC1 cells possessed similarly high invasive capacity on average, while 4T1 cells were 
characterized by the lowest invasion into Matrigel (Figure 12). 
Figure 12: Invasion capacity of 4T1, CTC1, 
and DTC1 cells. Left panel shows 
representative images of invasive 4T1, 
CTC1, and DTC1 cells stained with 
methylene blue. Right panel: Box-plot 
whiskers graphs show the quantification of 
invaded cells as OD590 from n ≥ 3 
independent experiments. 
 
 
 
 
As a short summary of the in vitro functional assays, one can deduce that EMT in CTC1 cells was 
reflected by a reduction of adhesion and proliferation, and by an increase in anchorage-independent 
invasion and growth. DTC1 cells with a partial EMT phenotype had generally improved capacities, 
with retained proliferation, increased adhesion, especially to endothelial cells, enhanced migration, 
invasion, and anchorage-independent cell growth. 
With the aim to compare the tumorigenic ability of 4T1, CTC1, and DTC1 cells and to obtain additional 
ex vivo CTC or DTC lines to study their EMT phenotypes, identical cell numbers were subcutaneously 
transplanted into the flank of BALB/c mice. After three weeks, mice were sacrificed and tumor weights 
were quantified. In this experiment, primary tumors, blood, bones, and organs were collected for the 
ex vivo selection of the primary tumor, CTC, DTC, and metastasis cell lines (See Methods 2.3).  
All 4T1- and DTC1-transplanted mice generated primary tumors (13/13 and 8/8, respectively). 
However, only 7 of 17 CTC1-injected mice generated primary tumors (41.2% frequency) (Figure 
13A). With respect to tumor weights, the DTC1-injected group of mice displayed the highest tumor 
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weights and also showed the biggest tumor sizes, which were determined with a Caliper measurement 
at the indicated time points in vivo (Figure 13A and B). The average tumor weight and size of the 
CTC1-injected group of mice were significantly reduced compared to the 4T1- and DTC1-injected 
groups of mice (Figure 13A and B). 
 
Figure 13: Tumorigenic ability of 4T1, CTC1, and DTC1 cells in vivo. (A) 4T1, CTC1, and DTC1 cell (1.25×105 cells) 
were subcutaneously transplanted in BALB/c mice. Shown are tumor weights with mean (horizontal line) for each group 
at the end of the experiment, including numbers of transplanted mice and numbers of tumor-bearing mice. (B) Line chart 
shows the tumor growth curves for 4T1-, CTC1-, and DTC1-injected groups of mice. Shown are means ± SD. 
 
IHC staining of epithelial marker EpCAM and mesenchymal marker Vimentin were performed in 4T1, 
CTC1, and DTC1 primary tumors. The result demonstrated that CTC1-derived primary tumors 
remained EpCAM-negative, similar to their parental CTC1 cells, whereas 4T1- and DTC1-derived 
primary tumors expressed EpCAM to a high level (Figure 14). 4T1-, CTC1-, DTC1-derived primary 
tumors had similar expression levels of Vimentin (Figure 14). This result provided proof that CTC1 
cells could generate primary tumors without re-expressing the epithelial marker EpCAM, however 
with a reduced penetrance of 42%. Furthermore, the CTC1-derived primary tumors- and metastases-
derived ex vivo cell lines retained a mesenchymal phenotype similar to their parental CTC1 cells. 
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Figure 14: Immunohistochemistry (IHC) staining of EpCAM and Vimentin in primary tumors of 4T1, CTC1, and DTC1 
cells-injected groups of mice. Left panels show representative images of IHC staining of EpCAM and Vimentin of 4T1, 
CTC1, and DTC1 primary tumors. IHC scores were quantified (see Methods 2.3.8) and are shown as bar charts of means 
± SD in the right panel.   
 
Incidences of ex vivo cultures retrieved from primary tumors, organs, blood, and bone marrows are 
shown in Figure 15A and B. Briefly, CTC1 and DTC1 were the only cell lines that were established 
from blood and bone marrow from 4T1-injected mice, and CTC1-transplanted mice group failed to 
establish any CTC or DTC cell line. In contrast, we could establish 26 CTC and10 DTC lines in 4 of 
8 and in 2 out of 8 DTC1-injected mice, respectively. In general, lungs displayed the highest frequency 
for the retrieval of metastatic cell lines as compared to liver, kidney, and spleen (Figure 15). 
Figure 15: Frequencies of ex vivo cultures of 4T1, CTC1, and DTC1 cells following syngeneic transplantation. (A) Ex vivo 
establishment of cell lines from primary tumors and metastatic lesions. Schematic representation of ex vivo retrieval of cell 
lines from primary tumors and metastatic sites (lung, spleen, liver, and kidney). The table shows the frequencies of 
successfully established cell lines from transplanted mice (input). (B) Ex vivo establishment of CTCs and DTCs. Schematic 
representation of ex vivo retrieval of CTC and DTC lines from blood and bone marrow. The table shows the frequencies of 
successfully established cell lines from transplanted mice (input). 
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Transplantation of identical cell numbers (1.25×105) of 4T1, CTC1, and DTC1 cells resulted in CTC1-
injected groups with significantly reduced tumorigenic potential compared to 4T1- and DTC1-injected 
groups of mice. In vitro, CTC1 showed comparably reduced proliferation, which could contribute to 
the formation of smaller tumors in vivo. In order to further explore the tumorigenic and metastatic 
potential of CTC1 cells, we performed a second round of transplantation experiments with increased 
numbers of injected of CTC1 cells. To do so, 1.25×105 (identical numbers for 4T1 and DTC1 cells), 5
×105, 1×106, and 2×106 CTC1 cells were subcutaneously transplanted into the flank of BALB/c mice 
(See Methods 2.3). After 15 days, mice were sacrificed, tumor weights were measured, and lungs were 
collected for metastasis colony formation assay. With increased numbers of injected cells, 1×106 and 
2×106 CTC1 groups reached similar tumor weights as 4T1- and DTC1-injected groups of mice (1.25
×105 injected cells) (Figure 16). However, the group of DTC1-injected mice with an injection of 1.25
×105 cells had significant bigger tumors than the group of CTC1-injected mice with an injection of 5
×105 cells (Figure 16). 
 
Figure 16: Tumorigenic ability of 4T1, DTC1, and CTC1 cells with increased cell numbers in the CTC1-injected group of 
mice. (A) 4T1 (1.25×105 cells; n = 5 mice), CTC1 (5×105 cells, 1×106, 2×106 cells, n = 10 mice per group) and DTC1 
cells (1.25×105 cells; n = 5 mice) were transplanted subcutaneously in BALB/c mice. Shown is a picture of all primary 
tumors. Dot plot on the right shows tumor weights with means (lines) of each group. (B) The line chart shows tumor growth 
curves with means ± SD, which were assessed in vivo with a Caliper measurement. 
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Metastasis formation assay was conducted to compare the metastatic ability of 4T1-, DTC1-, and 
CTC1-injected groups of mice. Four of 5 mice had generated lung metastases (80 %), both in the 4T1- 
and in the DTC1-injected group of mice. In the CTC1-injected group of mice, 5×105 and 1×106 cells 
generated lung metastases in 3 of 10 mice (30 % frequency), and mice after injection of 2×106 cells 
had lung metastases in 8 of 10 mice (80 % frequency) (Figure 17A). The average number of metastatic 
colonies was highest in DTC1-injected group, followed by 2×106 CTC1-injected group, 4T1-injected 
group, 1×106 CTC1-injected group, and the 5×105 CTC1-injected group showed the lowest number of 
the metastatic colonies (Figure 17B). The metastatic index per cell was defined as numbers of lung 
metastatic colonies divided by the numbers of injected cells. The metastatic index was used to compare 
the metastatic ability across all mice groups. As shown in Figure 17A, the metastatic index was highest 
in DTC1 mice group and lowest in 5×105 CTC1 group. In addition, metastatic indexes of CTC1-
injected groups were reduced compared to parental 4T1 cells (Figure 17A). To sum up, CTC1 cells 
have significantly decreased tumorigenic and metastatic capability compared to 4T1 and DTC1 cells. 
Figure 17: Metastatic potential of 4T1, DTC1, and CTC1 cells. (A) Dot plot graph shows metastatic index/cell with mean 
values (lines) and frequencies of lung metastasis per mouse. Metastatic index per cell was defined as numbers of lung 
metastatic colony divided by initially injected cell numbers. (B) Dot plot graph shows numbers of superficial metastatic 
colonies in each group.   
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3.3 EMT heterogeneity in DTC1-derived CTC lines  
In the present study, blood and bone marrows were collected for the isolation of CTC and DTC lines. 
In DTC1-injected mice, 26 CTC lines were isolated from 4 of a total 8 mice that had been transplanted. 
To confirm that the cell lines did not comprise white blood cells, the leukocyte marker CD45 was 
tested in all these cell lines by flow cytometry. Murine B cell lymphoma WEHI-231 cells represented 
a positive control for CD45 staining. The results demonstrated that all 26 CTC lines were CD45-
negative and thus, distinguished them from white blood cells (Figure 18). 
 
Figure 18: CD45 expression on DTC1-derived CTC lines. CD45 expression was measured in DTC1-derived CTC lines 
by flow cytometry with specific antibodies. CD45 staining is displayed in black lines, control staining is displayed in grey 
filled curves. Shown are representative histograms from n = 3 independent experiments. 
 
When observed under the microscope, these 26 CTC lines differed considerably with respect to their 
EMT phenotypes, which enabled us to further study the impact of EMT statuses on cellular functions. 
In order to classify the degree of EMT in these CTC lines, an EMT scoring system was introduced. 
This EMT scoring system combined the percentage of mesenchymal, spindle-shaped cells (0 - 100%) 
and the level of cell-cell contact (1 - 4; see Methods 2.2.15.9), to achieve an EMT score ranging from 
0 (epithelial, 4T1) to 400 (mesenchymal, CTC1). Figure 19B shows representative pictures of ex vivo 
cultured CTC lines with differing EMT scores to exemplify the phenotypic transition from epithelial 
to mesenchymal. The quantification of EMT scores is shown in Figure 19C, and the result reflected 
that EMT scores across all CTC lines were evenly distributed. EMT phenotypes of CTC lines varied 
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in different mice, but different EMT scores were also present in one individual mouse, i.e. in mice 
number 6 and 8 (Figure 19C). This demonstrated that CTCs with heterogeneous EMT phenotypes 
could co-exist in the blood of individual mice. 
Figure 19: EMT scores of DTC1-derived CTC lines. (A) Scheme of the experimental setup for the isolation of CTC lines. 
(B) Representative pictures of 4T1 and CTC1 cells, and DTC1-derived CTC lines representing various levels of EMT. The 
individual EMT scores are indicated in the bottom right of each picture. (C) Shown are mean EMT scores ± SD of 4T1-, 
CTC1-, and DTC1-derived CTC lines from n = 4 independent measurements. Mice of origin are color-coded as indicated 
in the bar graph. 
 
Based on the EMT scoring system, EMT phenotypes of CTC lines were divided into E-type (Epithelial, 
parental 4T1 cells), E/m-type (defined as primarily epithelial with a moderate transition to 
mesenchymal traits), M/e-type (defined as primarily mesenchymal with a moderate transition to 
epithelial traits), and M-type (mesenchymal, CTC1 cells). We selected three E/m- (CTC6-6, CTC6-11, 
CTC8-12) and three M/e- (CTC8-6, CTC8-5, CTC8-1) type DTC1-derived CTC lines to study whether 
EMT traits were associated with different cellular functions.  
First, immunocytochemistry staining was performed to test the protein expression of epithelial markers 
EpCAM and E-cadherin, and mesenchymal marker Vimentin. In M/e-type CTCs, a substantial 
reduction of the expression of EpCAM and E-cadherin was observed, however EpCAM and E-
cadherin were still expressed in a small proportion of cells. In contrast, E/m-type CTCs showed high 
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levels of EpCAM and E-cadherin (Figure 20). Vimentin expression was highly positive in all selected 
cell lines (Figure 20).  
Figure 20: Immunocytochemistry staining of control, Vimentin, EpCAM, and E-cadherin in E/m type (CTC6-6, CTC6-
11, CTC8-12) and M/e type (CTC8-6, CTC8-5, CTC8-1) CTCs. Shown are representative pictures from n = 3 independent 
experiment. Antigen staining is displayed in brown, cytoplasm and nuclei are counterstained with hematoxylin and eosin 
in blue. 
 
To compare the expression of classical EMT genes between E/m-type (CTC6-6, CTC6-11, CTC8-12) 
and M/e-type (CTC8-6, CTC8-5, CTC8-1) CTCs, quantitative RT-qPCR was conducted. The results 
reflected that the expression of the epithelial markers EpCAM, E-cadherin, and Rab25 was higher in 
E/m-type CTCs compared to M/e-type cells (Figure 21). mRNA levels of Ddr1, Grhl2, and Krt19 
were similar between E/m-type and M/e-type CTCs. EMT-related genes Vimentin, Slug, and Zeb2 
were significantly higher in the M/e-type CTCs. No statistical difference was found in expression of 
N-cad, Zeb1, ErbB2, ErbB3, Snail, and Twist (Figure 21).  
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Figure 21: Expression of EMT-related genes in E/m- and M/e-type CTCs. mRNA transcript levels of epithelial markers 
Epcam, E-cad, Rab25, Ddr1, Grhl2, and Krt19, and mesenchymal maker N-cad, Vimentin, Slug, Zeb1/2, Erbb2/3, Snail, 
and Twist in E/m-type (CTC6-6, CTC6-11, CTC8-12) and M/e-type (CTC8-6, CTC8-5, CTC8-1) CTCs derived from the 
blood of DTC1-transplanted mice were assessed by quantitative RT-PCR. Gusp mRNA expression served as house-keeping 
gene to normalize all samples. 4T1 cells were set to 1 as a reference. Bar charts show means ± SD from n = 3 independent 
experiments performed in triplicates. 
 
To address the influence of EMT on cellular functions, functional assays were performed in vitro.  
First, metabolism and proliferation were tested by MTT assay and cell counting. The results showed 
significantly higher cell metabolism and a 1.52-fold higher proliferation rate in the E/m-type group in 
comparison with the M/e-type group (Figure 22A and B). Furthermore, the adhesion and invasion 
capacities of each cell line were measured. Results disclosed that the adhesion property of E/m-type 
CTCs to endothelial cells, Matrigel, and Gelatin was significantly higher than that of M/e-type CTCs 
(Figure 23A). Furthermore, the invasion capacity of E/m-type cells was significantly, but only slightly 
increased (Figure 23B). 
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Figure 22: Cell metabolism and proliferation of E/m- and M/e- type DTC1-derived CTC lines. (A) The cell metabolism 
of E/m-type (CTC6-6, CTC6-11, CTC8-12) and M/e-type (CTC8-6, CTC8-5, CTC8-1) CTCs (initial seeding number 1,000 
cells) CTCs was assessed by MTT assay. Line chart shows cell metabolism as OD570 as means ± SD from n ≥ 3 independent 
experiments. (B) The proliferation of E/m-type (CTC6-6, CTC6-11, CTC8-12) and M/e-type (CTC8-6, CTC8-5, CTC8-1) 
CTCs (initial seeding number 5,000 cells) was assessed by cell counting at day 5. Shown are cell numbers as means ± SD 
from n ≥ 3 independent experiments. 
 
Figure 23: Adhesion and invasion assay of E/m- and M/e- type DTC1-derived CTC lines. (A) Adhesion assay to bEnd.3 
endothelial cells, Matrigel and Gelatin was performed with E/m-type (CTC6-6, CTC6-11, CTC8-12) and M/e-type (CTC8-
6, CTC8-5, CTC8-1) CTCs. Bar chart shows percentages of adherent cells as means ± SD from n ≥ 3 independent 
experiments. (B) Invasion ability of E/m-type (CTC6-6, CTC6-11, CTC8-12) and M/e-type (CTC8-6, CTC8-5, CTC8-1) 
CTCs were tested by transwell invasion assay. Box-plot whiskers graph shows OD590 as means with ranges from n ≥ 3 
independent experiments. 
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3.4 Mesenchymal-type CTCs are more resistant to chemotherapy than epithelial-
type CTCs 
Recent studies reported that EMT in tumor cells was associated with increased chemoresistance 
(Fischer et al., 2015; Lambert et al., 2017). To test the response to chemotherapeutics in relation to the 
EMT status of the tested cells, E (4T1), E/m- (CTC6-6, CTC6-11, CTC8-12, DTC1), M/e- (CTC8-6, 
CTC8-5, CTC8-1), and M-type (CTC1) cells were cultured in medium containing Cisplatin or 
Doxorubicin at increasing concentrations for 48 h. Metabolic activity, which was an indication of cell 
viability, was detected by MTT assay. IC50 values define the concentration of drug that results in a 50% 
reduction of cell growth. Mesenchymal-type cells (M-, M/e- type) were characterized by increased 
chemoresistance in comparison with epithelial-type (E-, E/m- type) cells, both for Cisplatin (IC50 mean 
values: M: 18.81 ± 3.40 μM, M/e: 18.12 ± 7.33 μM, E: 10.37 ± 4.15 μM, E/m: 11.35 ± 3.16 μM) 
and for Doxorubicin (IC50 mean values: M: 4.51 ± 0.30 μM, M/e: 3.05 ± 2.04 μM , E: 0.66 ± 0.59 
μM, E/m: 0.93 ± 0.52 μM) (Figure 24). Hence, M- and M/e- type CTC lines showed increased 
resistance towards clinical chemotherapeutic drugs, as compared with E- and E/m- type CTCs. 
 
Figure 24: Chemoresistance of E-, E/m-, M/e-, and M- type cells. Chemoresistance towards Cisplatin and Doxorubicin 
was tested across a concentration range of 1.875 - 120 μM by MTT assay in the indicated cell lines. Line charts show cell 
viability as means ± SD from n ≥ 3 independent experiments. Statistical analysis was done by comparing IC50 values.   
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3.5 E/m-type CTCs possess highest lung metastasis formation ability in vivo 
In vitro assays showed that E/m-type CTCs had increased proliferation, adhesion, and invasion rates 
compared to M/e-type CTCs, whereas M/e-type CTCs had increased chemoresistance. CTCs are cells 
in the bloodstream and are regarded as the main source of metastasis-initiating cells. To compare CTCs 
with differing EMT phenotypes for their capacity to form lung metastases, we performed intravenous 
(i.v.) injections. To do so, E-type (4T1), E/m-type (CTC6-6, CTC6-11, CTC8-12, and DTC1 as 
control), M/e-type (CTC8-6, CTC8-5, CTC8-1), and M-type (CTC1) cells were injected in the tail vein 
of BALB/c mice (identical cell number, 5×104 cells) (Figure 25A). After 19 days, mice were sacrificed 
and lung metastasis was assessed by counting superficial metastases and by ex vivo metastasis colony 
formation assay. The metastatic index was calculated as numbers of lung metastatic colonies divided 
by the numbers of intravenously injected cells. As shown in Figure 25 B, C, and D, epithelial-type (E, 
E/m) cells had a significantly improved metastasis-inducing ability in comparison with mesenchymal 
cells (M, M/e) cells. Especially, E/m-type CTCs exhibited the best capacity to form lung metastasis 
and had an average 9.13-fold higher metastatic index than M/e-type cells, a 2.41-fold higher than E-
type cells, and a 98.98-fold higher than M-type cells (Figure 25 B, C, and D). 
Given that M/e- and M-type cells possessed reduced proliferation capacity compared to E- and E/m-
type cells, differences in forming lung metastasis might result from longer latencies in vivo, and not 
from inherently decreased metastatic capacities. To address this eventuality, E/m-type CTC6-6 cells 
(highest metastatic ability; as positive control group), M/e-type cells (CTC8-6, CTC8-5, and CTC8-1), 
and M-type CTC1 cells were injected intravenously into the tail vein of BALB/c mice (each 5 mice 
per cell line). The aim of this mouse experiment was to observe the metastatic potential over prolonged 
time periods. Hence, mice were observed daily for signs for an endpoint (Methods 2.3.6). The defined 
endpoints were: (1) substantial weight loss (more than 5% in more than two mice out of five), (2) 
weakness, i.e. tiredness, unresponsiveness (more than 2 mice out of five), (3) ≤ 2 remaining 
experimental groups. After 22 days, 5 of 5 E/m-type CTC6-6-injected mice (100%) and 1 out of 5 
CTC8-1-injected mice (20%) displayed substantial weight loss, weakness, and dyspnoea, and had to 
be sacrificed (Figure 26A). Severe lung metastases were defined as ≥ 10 metastases per lung. Upon 
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autopsy, all mice ended on day 22 had severe lung metastases, and metastatic colony formation assay 
confirmed these results (Figure 26 D and E). On day 25, the remaining 4 mice (80%) in the CTC8-1-
injected group and all 5 mice (100%) in the CTC8-5-injected group displayed signs for an endpoint. 
In these groups, 2 of 9 mice were diagnosed with severe lung metastases (22.2%), 4 of 9 mice (44.4%) 
had metastases near larger bones, and 3 of 9 mice showed multiple tumor sites (33.3%) (Figure 26A). 
At day 28, all mice in the CTC8-6-injected group presented substantial weight loss and weakness. 
Mice in the CTC1-injected group did not display weight loss or weakness. These two groups were 
sacrificed and analyzed at day 28. None of the CTC8-6-injected mice showed severe lung metastases 
(0%), but all 5 mice had metastases near big bones (100%), and 3 of 5 mice had multiple metastases 
(60%) (Figure 26 A and B). Through autopsy, CTC1-injected mice did not show any metastasis in 
the lungs, only 2 of 5 mice were bearing small tumors at the injection site in the tail area (Figure 26A). 
Numbers of superficial lung metastases were counted manually, and numbers of ex vivo metastatic 
colonies and metastatic indexes are shown in Figure 26C and Figure 26D and E. Results confirmed 
that E/m-type CTC6-6 cells had a significantly higher metastatic index compared to M/e- and M- type 
cells, even after extended observation time. Substantial weight loss of the injected animals, as a 
surrogate sign of clinical disease progression, was also first observed in CTC6-6 group (Figure 26F). 
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Figure 25: Lung metastasis formation by E-, E/m-, M/e-, M- type cells. (A) Scheme of i.v. injection: Epithelial E-type 
(4T1), E/m-type (CTC6-6, CTC6-11, CTC8-12, DTC1), M/e-type (CTC8-6, CTC8-5, CTC8-1), and mesenchymal M-type 
(CTC1) cells (5×104) were transplanted into BALB/c mice through tail vein intravenous injection. After 19 days, numbers 
of superficial lung metastasis were counted and lungs were harvested for further metastasis colony formation assay. (B) 
Metastatic index per cell for each cell line. Left: Shown are representative pictures of lungs following i.v. injection. Right: 
Dot plot graph shows metastatic index with means (lines). (C) Dot plot graph shows numbers of metastases counted in the 
lungs with means (lines). (D) Dot plot graph shows numbers of colonies counted in metastasis colony formation assay with 
means (lines). Injected numbers of mice: n4T1 = 8, nCTC1 = 8, nDTC1 = 14, nCTC6-6 = 6, nCTC6-11 = 5, nCTC8-12 = 6, nCTC8-6 = 6, 
nCTC8-5 = 6, nCTC8-1 = 6. 
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Figure 26: Metastasis formation by E/m-, M/e-, and M- type CTCs. (A) Scheme of i.v. injection experiment: E/m-type 
(CTC6-6), M/e-type (CTC8-6, CTC8-5, CTC8-1), and mesenchymal M-type (CTC1) cells were transplanted to BALB/c 
mice through intravenous tail vein injection. Experimental groups were ended at the day of the indicated signs for a pre-
defined endpoint. Results from autopsy at the given time points are described in the table. (B) Shown are pictures of autopsy 
results from CTC8-6-injected mice displaying the lack of lung metastasis, tumors in the vicinity of the rib, tibiae, and 
shoulder blade. (C) Shown is the metastatic index per cell of E/m-type (CTC6-6), M/e-type (CTC8-6, CTC8-5, CTC8-1) 
and mesenchymal M-type (CTC1) cells with means (lines) and P values as indicated. (D) Dot plot graph shows numbers 
of metastases counted in the lungs with means (lines) and P values as indicated. (E) Dot plot graph shows numbers of 
colonies counted in metastasis colony formation assay with means (lines) and P values as indicated. (F) Shown is weight 
growth curves for each group as means ± SD.  
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3.6 EMT in CTC lines is not a mere reflection of cell heterogeneity in 4T1 and 
DTC1 cells 
4T1 cells and DTC1 cells are characterized by high genetic alterations, which could be a reason for 
the heterogeneous EMT phenotypes observed in CTC lines. In other words, the observed EMT 
heterogeneity in CTC lines might be the result of a clonal selection of pre-existing EMT phenotypes, 
rather than an actual induction of EMT during the metastatic cascade. To test this hypothesis, single 
cell clones (SCCs) of 4T1 (n = 30), CTC1 (n = 23), and DTC1 (n = 30) were generated in vitro and 
compared with ex vivo DTC1-derived CTC lines (n = 26). EMT scores were assessed and EpCAM 
expressions were measured by flow cytometry in 4T1-, CTC1-, and DTC1- derived SCCs. EMT scores 
of 4T1-SCCs were ranged from 0 to 80, reflecting a high proportion of cells with an epithelial 
phenotype. EMT scores of CTC1-SCCs were ranged from 380 to 400, which confirmed a predominant 
mesenchymal phenotype in CTC1-SCCs. The largest variation in EMT scores amongst single cell 
clones was observed in DTC1-SCCs, with EMT scores ranging from 0 to 150. However, DTC1-
derived CTC lines had EMT scores ranging from 0 to 360 (Figure 27A and B). Therefore, the range 
of EMT in DTC1-derived CTC lines was substantially broader than in DTC1-SCCs, CTC1-SCCs, or 
4T1-SCCs, and thus, it was not simply a result of the heterogeneity of 4T1 cells in general. Variances 
(squared standard deviations) of SCCs and DTC1-derived CTC lines were calculated and compared. 
Significant differences in EMT scores were found between DTC1-SCCs (range 90, variance 736.86) 
and DTC1-derived CTC lines (range 345, variance 14428.12) (Figure 27B).  
EpCAM expressions were measured in 4T1-, CTC1-, and DTC1-SCCs and compared with DTC1-
derived CTC lines. 4T1-SCCs had the largest variance (344.77), which might be attributed to a 
generally very high EpCAM level in 4T1 cells. Similar to EMT scores, DTC1-derived CTC lines had 
a wider distribution of mean EpCAM expression levels with increased variance and range compared 
to DTC1-SCCs (Figure 27C). In conclusion, these data demonstrated that EMT phenotypes in DTC1-
derived CTC lines were not the sole result of the heterogeneity of parental 4T1 or DTC1 cells. 
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Figure 27: EMT scores and EpCAM expressions in 4T1-, CTC1- and DTC1-SCCs and in DTC1-derived CTC lines. (A) 
Shown are representative pictures of 4T1-, CTC1-, DTC1- SCCs, and DTC1-derived CTC lines (n = 26) for the highest 
and lowest EMT scores. Individual EMT scores are indicated within each picture. (B) Dot plots show mean values of EMT 
scores from n = 3 independent scores in 4T1-, CTC1-, and DTC1-SCCs, and DTC1-derived CTC lines. Black lines 
represent means of EMT scores for all 4T1-, CTC1-, and DTC1-SCCs, and DTC1-derived CTC lines. (C) Dot plot graph 
shows means of EpCAM expression from n = 2 independent measurement in 4T1-, CTC1-, and DTC1- SCCs, and DTC1-
derived CTC lines. Black lines represent means of EpCAM expression for all 4T1-, CTC1-, and DTC1- SCCs, and DTC1-
derived CTC lines. Data are additionally shown as frequency diagrams with variance (squared value of standard deviation) 
and range (difference between lowest and highest values) (right panel). 
RESULTS 
61 
 
3.7 EpCAM expression is negatively correlated with EMT 
EpCAM is an epithelial marker that is widely used to detect and isolate CTCs from the blood of cancer 
patients. However, cells can lose EpCAM expression during EMT (Gorges et al., 2012). To test 
whether EpCAM expression in DTC1-derived CTC lines was related to EMT, a Spearman’s rank 
correlation test was performed to analyze a potential correlation between EpCAM expression and EMT 
score. The result proved that the expression of EpCAM was negatively correlated with the EMT score 
(r = -0.728, P < 0.001) (Figure 28). This finding further indicated that CTCs that undergo EMT would 
lose EpCAM and escape from EpCAM-dependent CTC isolation using enrichment techniques. 
 
Figure 28: Cluster plot analysis of Spearman’s rank correlation between EpCAM expression and EMT score in DTC1-
derived CTC lines. P value and r value are indicated. 
 
3.8 EpCAM expression is higher in metastatic sites compared with primary tumors 
After subcutaneously transplanting 4T1, CTC1, and DTC1 cells in BALB/c mice, ex vivo cultured cell 
lines were established from primary tumors, blood, bones, and metastases. EpCAM expression in these 
cell lines was measured by flow cytometry (Figure 29).  
In 4T1-derived cell lines, EpCAM was down-regulation in a proportion of the primary tumor cell 
sublines compared to parental 4T1 cells, while metastatic cell lines presented generally high EpCAM 
expression (Figure 29A). EpCAM was significantly higher in metastases comparing to primary tumors. 
Furthermore, EpCAM remained absent in CTC1-derived primary tumors and metastatic cell lines 
(Figure 29B). Former IHC staining of EpCAM in CTC1 primary tumors was also negative. 
Accordingly, CTC1-derived primary tumor and metastatic cells maintained a mesenchymal phenotype 
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in ex vivo culture conditions. This result further suggested that tumor cells can form primary tumors 
and metastases without considerable MET, although with decreased frequency. In DTC1-derived cell 
lines, EpCAM expression was higher in DTCs and metastasis-derived cell lines compared to CTCs 
and primary tumor cell lines (Figure 29C). Furthermore, DTC1-derived CTC lines displayed 
significant heterogeneity of EpCAM expression (Figure 29C). 
Referring to the results of the former mouse experiment, showing that E/m-type cells possessed the 
highest metastatic ability, higher EpCAM expression in metastases could be the consequence of E/m-
type CTCs being the primary source of metastasis. 
 
Figure 29: EpCAM expression of 4T1-, CTC1-, and DTC1-derived cell lines. EpCAM expression was tested by flow 
cytometry in cell lines from primary tumors (PT), CTCs, DTCs, and metastases isolated from 4T1-, CTC1-, and DTC1-
injected BALB/c mice. (A) Bar chart shows EpCAM expression in 4T1-derived cell lines as the mean fluorescence intensity 
ratio (MFI-R) ± SD from n ≥ 3 independent measurements. (B) Bar chart shows EpCAM expression in CTC1-derived cell 
lines as the MFI-R ± SD from n ≥ 3 independent measurements. (C) Bar chart shows EpCAM expression in DTC1-derived 
cell lines as the MFI-R ± SD from n ≥ 3 independent measurements. Cell lines originating from the same mouse were 
marked with brackets. L: lung, S: spleen, K: kidney, LN: lymph node.  
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Figure 30: EpCAM expression in primary tumors and corresponding metastases in patients with MBC. (A-B) EpCAM 
expression was assessed in n = 38 breast cancer patients. Shown are representative IHC stainings of EpCAM in primary 
tumors and corresponding metastatic sites (lung, liver, bone marrow, lymph node), and the quantification of EpCAM IHC 
scores of paired tumor and metastases samples are shown as paired line charts.  
 
In the 4T1 mouse model, EpCAM was expressed to higher levels in metastatic sites compared to 
primary tumors. To explore whether comparable observations could be done in patients with MBC, 
pairs of primary tumors and corresponding lymph node metastases (n = 12), liver metastases (n = 10), 
lung metastases (n = 8), and bone metastases (n = 8) were obtained from breast cancer patients after 
surgery. IHC staining of EpCAM expression was performed at the Shanghai General Hospital, 
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Shanghai, China. The results of EpCAM IHC scores confirmed that EpCAM levels were higher in 
metastases compared to primary tumors (Figure 30 A and B), which was similar to the findings in the 
4T1 mouse model. 
3.8 The EpCAM-positivity rates in DTCs is related to metastasis and predicts 
survival in patients with MBC 
To extend our findings, an EpCAM-independent CTC isolation technology that integrates subtraction 
enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) was used to assess the 
EMT status of CTCs and DTCs in patients with MBC (Lin, 2015). In collaboration with Prof. Hongxia 
Wang ś group (Shanghai General Hospital, China), CTCs and DTCs were isolated by multi-marker 
subtraction enrichment (Methods 2.2.16). In total, n = 34 patients with breast cancer stage III - IV were 
recruited from September 2015 to April 2017. The characteristics of patients are shown in Figure 31. 
Patients were newly diagnosed with MBC and have received standard care at the Shanghai General 
Hospital. The age of patients ranged from 28 to 76 years, with a median of 57 years. The majority of 
these patients were suffering from stage IV MBC (67.65%) and had the intrinsic subtype of luminal B 
breast cancer (44.12%). All patients were followed for a median of 11 months. Lungs and bones were 
the main sites of metastases (both represented 14.71% of the metastatic sites, each). 
In the current study, CTCs and DTCs were isolated from blood and bone marrow, respectively. Blood 
and bone marrow samples were firstly deprived of red blood cells, and the remaining cells were 
detected with CD45-specific antibody to exclude white blood cells. In situ hybridization with 
chromosome enumeration probes hybridizing to human chromosome 8 (CEP8) was conducted to 
assess the ploidy status of each single cell (Figure 32). Aneuploidy on chromosome 8 was frequently 
observed using CEP8 in breast cancer, and thus the CEP8 status served to identify cancer cells in the 
blood and bone marrow (Lin, 2018). EpCAM expression was examined in the enriched cell population. 
As shown in Figure 32, CTCs and DTCs were identified as CD45-negative, DAPI-positive, CEP8-
aneuploid and EpCAM positive or negative cells, or CEP8-diploid EpCAM positive cells.  
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Figure 31: Characteristics of patients. Shown 
are clinical parameters for n = 34 patients with 
MBC, including gender, age, tumor stage, 
intrinsic subtype, follow-up time, metastatic 
status, and CTC and DTC numbers. 
RESULTS 
66 
 
 
Figure 32: SE-iFISH enrichment and detection of CTCs and DTCs. Immunofluorescence staining of CD45 (red), DAPI 
(blue), EpCAM (green), and CEP8 (orange) are depicted as indicated. CTC and DTC, and tumor cell clusters are indicated 
by white arrows. Shown are representative examples as indicated. EpCAM-pos: EpCAM-positive; EpCAM-neg: EpCAM-
negative. 
 
A total number of 845 CTCs and 71,910 DTCs were detected from n = 34 patients with MBC. The 
median cell numbers detected per patient were 9 CTCs and 413 DTCs, respectively. As shown in 
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Figure 33 A and B, the overall numbers of CTCs were less than of DTCs per patient, and the numbers 
of cell clusters were also significantly higher in DTCs compared to CTCs. 
The EpCAM-positivity rate was defined as the number of EpCAM-positive cells divided by the total 
number of detected cells in each patient. The EpCAM-positivity rate was found higher in DTCs 
compared to CTCs, which is in line with the result obtained in the 4T1 mouse experiment (Figure 
33C).  
 
Figure 33: Paired CTCs and DTCs numbers. (A) Paired line chart shows the numbers of CTCs and DTC detected in n = 
34 MBC patients. Each line represents one patient. (B) Paired line chart shows the numbers of cell clusters. Each line 
represents a patient. (C) Paired line chart shows the EpCAM positive rate in each patient. Each line represents a patient.  
 
The proportion of patients containing EpCAM-positive cells is shown in Figure 34. Twenty of 34 
patients (58.8%) did not contain detectable EpCAM-positive CTCs in their blood. In contrast, only 12 
patients (35.3%) had no EpCAM-positive DTCs in their bone marrow (Figure 34). Referring to the 
entirety of detected CTCs and DTCs, the proportion of EpCAM-positive CTCs and DTCs was 22.4% 
and 65.9%, respectively (Figure 34). The ploidy statuses of CTCs and DTCs are shown in Figure 35A. 
Triploid (36.6%) and tetraploid (36.3%) represented the highest proportion of CTCs and DTCs, 
respectively. Cell size was compared referring to WBC, and the majority of cells had a size similar to 
WBC (50.7% in CTCs and 77.0% in DTCs, respectively) (Figure 35B). Figure 36 further shows the 
ploidy status of CTCs and DTCs in relation to cell size. For cells larger than WBC, 64.6% of CTCs 
and 84.6% of DTCs had CEP 8 numbers larger than 3. 
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Figure 34: Proportion of EpCAM expression in CTCs and DTCs. Pie charts show the proportion of MBC patients 
containing EpCAM-positive cells (left) and the EpCAM expression status of all detected cells (right). EpCAM-positive 
and -negative proportions are depicted in blue and red, respectively. 
. 
 
Figure 35: Pie charts show (A) the ploidy status of CTCs and 
DTCs, and (B) the cell size compared with WBC 
 
 
 
 
 
 
 
 
Figure 36: Ploidy status of CTCs and DTCs in relation to 
the cell size, referring to smaller, similar, and larger than 
WBC. Ploidy statuses are colour-coded as indicated and are 
given in percentages. 
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The expression of EpCAM was negatively correlated to the EMT status of cells and the EpCAM-
positivity rate reflected the proportion of epithelial tumor cells in CTCs and DTCs derived from the 
4T1 mouse model. Therefore, the EpCAM-positivity rate was applied as a parameter to stratify n = 34 
MBC patients and to predict the patient’s metastatic status and clinical outcome. The results showed 
that the EpCAM-positivity rates of CTCs and DTCs were higher in patients with detectable organ 
metastasis (M1), compared to patients without (M0) (Figure 37A). In addition, higher EpCAM-
positivity rates in DTCs were significantly associated with the occurrence of lung metastases (Figure 
37A). All patients were followed for a median of 11 months. A receiver operating characteristic (ROC) 
curve analysis was conducted to assess the efficiency of the EpCAM-positivity rate to predict the 6-
months survival of patients. The EpCAM-positivity rate of DTCs, but not CTCs, allowed to predict 
the risk of 6-months mortality (Figure 37B; AUC = 0.785, 95% CI 0.588 – 0.983; P = 0.018). A cut-
off value of 19.78% EpCAM expression was further obtained, with a sensitivity and specificity of 75.0% 
and 82.6%, respectively. Based on the results of the ROC analysis, we used a 20% EpCAM-positivity 
rate as a cut-off value to predict the overall survival of patients with MBC. The Kaplan-Meier survival 
analyses demonstrated that patients with EpCAM-positivity rates of ≥ 20% in DTCs had substantially 
poorer overall survival (Figure 37C).  
Considering diploid EpCAM-positive cells could be normal epithelial cells that in the blood of patients, 
EpCAM-positivity rates of CTCs and DTCs were re-calculated by excluding diploid EpCAM-positive 
cells. Shown in Figure 37 D, E, and F, the results were similar to the results obtained when including 
diploid EpCAM-positive cells. However, a significant difference was observed in the EpCAM-
positivity rates of aneuploid CTCs between patients with and without lung metastases. The proportions 
of EpCAM-positive aneuploid DTCs could also predict the 6-months mortality in patients with MBC 
(AUC = 0.793, 95% CI 0.599 – 0.988; P = 0.015), and the cut-off value decreased to 16.87% (Figure 
37E). Hence, we applied a 15% EpCAM-positivity rate as a cut-off value to predict the patients’ 
outcome. The Kaplan-Meier curves demonstrated that patient with EpCAM-positive aneuploid DTCs 
≥ 15% had a substantially poorer outcome (Figure 37F). 
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Figure 37: EpCAM-positivity rate as a clinical parameter is associated with the patient’s metastatic status and can predict 
the clinical outcome. EpCAM+: EpCAM positive. (A and D) Dot plot graph shows the percentage of EpCAM-positive 
CTCs and DTCs per patient (n = 34) and is stratified according to distant metastases statuses M0 and M1, and the presence 
or absence of lung metastases ((A) includes EpCAM-positive diploid cells, (D) excludes EpCAM-positive diploid cells). 
(B and E) Receiver operating characteristic (ROC) curves predict 6 months survival of patients with MBC ((B) includes 
EpCAM-positive diploid cells, (E) excludes EpCAM-positive diploid cells). The area under the curve (AUC) and P value 
are presented. (C and F) Kaplan-Meier survival curves show overall survival of patients (n = 34) with EpCAM-positivity 
rate cutoff values of 20% (C) and 15% (F) in DTCs ((C) includes EpCAM-positive diploid cells, (F) excludes EpCAM-
positive diploid cells). 
 
In summary, the EpCAM-positivity rates of CTCs and DTCs are useful markers to predict the risk of 
metastasis, the 6-months survival, and the overall survival of patients. These clinical data strongly 
supported the results of the 4T1 mouse model, in which EpCAM-positive CTCs (E- and E/m- type 
cells) were correlated with the generation of lung metastasis and poorer outcome.
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4. DISCUSSION 
In the current study, the 4T1 MBC mouse model comprehensively recapitulated the different stages of 
tumor progression including the formation of primary tumors, the systemic dissemination of cancer 
cells, and, ultimately, the formation of organ metastases. Based on the in-depth analysis of the EMT 
heterogeneity of 4T1-derived CTC lines, we found that epithelial tumor cells with a limited 
mesenchymal transition were the main reservoir of metastasis-inducing systemic cancer cells. 
EpCAM, as a marker of epithelial cells, was reduced in expression or entirely lost in breast carcinoma 
cells undergoing EMT. On the basis of this regulation, we used the EpCAM-positivity rate in CTCs 
and DTCs as a surrogate marker for their EMT status, and could show an association with the 
metastatic status and clinical outcome in clinical samples of patients with MBC. 
4.1 The 4T1 metastatic mouse model 
The 4T1 breast cancer model is a well-established animal model that recapitulates the process of tumor 
progression, including the formation of primary tumors, CTCs, DTCs, and, eventually, distant 
metastases (Aslakson and Miller, 1992; Miller et al., 1987). 4T1 cells were first isolated from a lung 
metastasis in a breast cancer-bearing mouse through in vivo selection by 6-TG (Aslakson and Miller, 
1992; Miller et al., 1981). As a breast cancer cell line, 4T1 cells have a typical epithelial phenotype 
with compact cell-cell connections and a cobblestone-like morphology. In the present study, 4T1 cells 
were subcutaneously transplanted in the flank of BALB/c mice to generate primary tumors. CTC lines 
were isolated at late stages of tumor formation (i.e. 3 weeks following transplantation) from the blood 
of tumor-bearing animals. CTCs were selected based on their resistance to 6-TG, as opposed to normal 
blood cells, which are vulnerable to 6-TG. Potential DTC lines were isolated in a similar manner from 
the bone marrow of transplanted mice at the same time points. By doing so, one CTC and one DTC 
line were generated following the transplantation of 4T1 cells. CTC1 had a strong mesenchymal 
morphology with loose cell-cell contact, complete loss of EpCAM expression, and distinct spindle 
shape. All these features reflect a pronounced EMT in CTC1. The DTC1 cells showed a hybrid EMT 
phenotype (E/m-type), with a majority of cells remaining in an epithelial state and a subpopulation of 
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cells that have acquired a more mesenchymal phenotype. This was accompanied by an overall 50% 
decrease of EpCAM expression in comparison with 4T1 cells. Hence, CTC1 and DTC1 cells presented 
two different statuses of EMT: CTC1 were in a complete mesenchymal transition, whereas DTC1 cells 
appeared in a stage of partial EMT. These results confirmed that EMT occurred during the metastatic 
cascade in the 4T1 model. Furthermore, the results are also in strong support of the notion that EMT 
represents a gradual process with different cellular stages in cancer, rather than an “all-or-nothing” 
process. 
In vitro functional assays performed in the course of the study further show that CTC1 cells have 
increased invasion and anchorage-independent cell growth, while decreased proliferation and adhesion 
compared with parental 4T1 cells. DTC1 cells were characterized by a hybrid EMT type in which they 
have retained in a proliferative state, are more adhesive to endothelial cells, and possess enhanced 
invasion and anchorage-independent cell growth. Therefore, it can be suggested that DTC1 cells have 
made an evolution compared to 4T1 cells through a partial EMT, that allowed them to adapt to the 
tumor microenvironment. DTC1 cells seem to have undergone an EMT to a degree sufficient to 
provide them with the above mentioned mesenchymal traits (i.e. invasion, migration), without 
suffering the loss of proliferation and the ability to form cell contacts. Oppositely, full EMT as 
observed in CTC1 cells generates more quiescent cells with improved anchorage-independent growth. 
However, these features were gained at the expense of the strong capacity to form primary tumors and, 
even more so, metastases in the lungs. Recently, Kröger C et al. reported a hybrid E/M phenotype that 
is important for the tumorigenicity of carcinoma cells, which cannot be phenocopied by simply mixing 
E- and M-staged tumor cells together. These findings demonstrated that the hybrid E/M state of tumor 
cells is an independent cell phenotype that is highly relevant in tumor progression (Kroger et al., 2019). 
In order to isolate more CTC and DTC lines to study the effect of EMT on metastasis formation, 4T1, 
CTC1, and DTC1 cells were re-transplanted into BALB/c mice. It was frequently reported that CTCs 
in general are rare in the blood, with less than 1 CTC in ten million WBCs in patients with MBC 
(Cristofanilli, 2006; Janni et al., 2016a). In the 4T1 mouse model, only one CTC line (CTC1) was 
established after transplantation of parental 4T1 cells and no CTC line was retrieved from CTC1-
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injected mice. Hence, these results reflected and further confirmed the extremely low numbers of CTCs 
reported in the blood of patients. An additional reason for the observed low incidence of ex vivo 
cultured CTCs and DTCs could be based on differences between in vivo and ex vivo culture conditions, 
where CTCs and DTCs may be not able to grow in an ex vivo culture environment. It is conceivable 
that soluble and cellular factors present in the microenvironment in vivo are essential for CTCs and 
DTCs, which will be lacking under ex vivo culture conditions. For example, Min Y et al. could culture 
MBC patient-derived CTC lines in ultralow attachment plates in RPMI-1640 medium supplemented 
with epidermal growth factor (20 ng/mL), basic fibroblast growth factor (20 ng/mL), B27 (10 mL), 
and antibiotic/antimycotic. However, their CTC lines were unable to grow in other culture media (i.e. 
MCF10A medium and Mammary Epithelial cell Growth Medium) (Yu et al., 2014). Despite potential 
issues in the ex vivo culture of CTCs and DTCs from the 4T1 mouse model, we didn’t observe any 
bias in EMT phenotypes of ex vivo established CTC lines, which demonstrated that the culture method 
applied in the current study did not select for particular EMT types. Selection with 6-TG did also not 
impact on the epithelial status of 4T1 in culture, as was shown in long-term cultures. 
In summary, the 4T1 breast cancer mouse model allowed to recapitulate all major aspects of breast 
cancer generation and progression in the presence of an intact immune system. It was further confirmed 
that EMT occurs in systemic cancer cells, and that CTCs and DTCs represent rare cells in the blood 
and bone marrow of mice. 
4.2 EMT phenotypes of DTC-derived CTC lines 
In the group of DTC1-injected mice, 26 CTC lines were successfully established ex vivo. Given the 
low numbers of cancer cells appearing in the blood and because selection of CTCs with 6-TG occurred 
in serial dilutions in a 96-well format, the resulting CTC lines most likely originated from either mono- 
or oligoclones. The cell morphology differed considerably across these 26 CTC lines, but was however 
stable within cell lines, further supporting the notion that they represent different mono- or oligoclones. 
In order to compare the degree of EMT across these CTC lines, an EMT scoring system was 
introduced. This EMT score system was built by reference to the widely used IHC scoring system, as 
a product of two fundamental EMT parameter, namely the level of cell-cell connection and the 
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percentage of spindle-shaped cells within a given cell population. Owing to the heterogeneity of 4T1 
carcinoma cells (Roulot et al., 2016; Wang et al., 2017b), the EMT phenotypes observed in ex vivo 
selected CTC lines could have been the result of a tumor heterogenicity that is intrinsic to the parental 
4T1 population, rather than an EMT fulfilled during the metastatic cascade in vivo. Hence, it was 
important to provide evidence that differences in EMT phenotypes of 4T1 derivative cell lines were 
indeed the result of an EMT performed in vivo. To do so, single cell clones of 4T1 (n = 30), CTC1 (n 
= 23), and DTC1 (n = 30) cells were generated in vitro, in order to assess an EMT in these clones. 
Clearly, EMT shifts observed in 4T1- and DTC1-SCCs were significantly inferior to the EMT 
variations detected in DTC1-derived CTC lines. Hence, a substantial degree of the observed EMT 
measured in CTC lines must have occurred in vivo after transplantation of 4T1 and DTC1 cells. 
Recent evidence demonstrated that EMT was not an “all-or-nothing” event and that cancer cells usually 
acquire hybrid EMT phenotypes, i.e. E/m- or M/e-types (Brabletz et al., 2018a; Huang et al., 2013; 
Jordan et al., 2011; Lambert et al., 2017; Pastushenko et al., 2018; Sikandar et al., 2017; Thompson 
and Nagaraj, 2018; Yu et al., 2013). As mentioned, DTC1-derived CTC lines showed a substantial 
diversity in EMT phenotypes, which allowed us to further subdivide CTCs into E/m- and M/e- 
phenotypes. Because our EMT scoring system was based on morphological criteria rather than on 
genetic criteria, we opted to divide CTCs only into two major types, i.e. an E/m- and an M/e-type, to 
reflect their stages of epithelial and mesenchymal transitions. These E/m- and M/e-phenotypes 
observed in the 4T1 model replicate the frequently discussed partial EMT in tumor cells (Chaffer et 
al., 2016; Nieto et al., 2016; Voon et al., 2017), and support the notion that tumor cells do undergo a 
limited EMT. We selected three E/m- and M/e-type CTC lines each for further in vitro functional 
characterization and in vivo metastasis formation analysis. Functional characterization showed that 
E/m-type cells have increased invasion, proliferation, and adhesion capacities compared to M/e-type 
CTCs. The mRNA transcript levels of the epithelial markers Epcam, E-cadherin, Rab25 were 
significantly higher in E/m-type cells, whereas the mesenchymal maker Vimentin, Slug, and Zeb2 
were expressed to higher levels in M/e-type cells. No differences were observed in the expression 
levels of Ddr1, Grhl2, Krt19, N-cad, Vim, Slug, Zeb1, Erbb2/3, Snail, and Twist. Hybrid EMT 
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phenotypes were also addressed in ovarian and breast cancer cells (Huang et al., 2013; Yu et al., 2013). 
Huang et al have defined EMT groups similar to ours: epithelial, intermediate epithelial, intermediate 
mesenchymal, and mesenchymal, and have analyzed the correlation between EMT phenotypes and the 
outcome of patients suffering from a broad spectrum of carcinomas, comprising breast cancer (Huang 
et al., 2013; Tan et al., 2014). In the current study, we tested EMT-related genes, including Ddr1, 
Grhl2, Krt19, N-cad, Vim, Slug, Zeb1, Erbb2/3, Snail, and Twist, as referenced by Tan et al. (Tan et 
al., 2014), in nine cell lines with different EMT statuses (4T1, CTC1, DTC1, E/m-, and M/e- type 
cells). Although we observed significant differences across CTC lines, the expression pattern of some 
EMT genes revealed unexpected. For instance, EMT-inducing genes Twist and Snail were decreased 
in the mesenchymal CTC1 cell line, as compared to 4T1 and DTC1 cells. As the EMT program is 
controlled by complex pathways and since plenty of genes can be involved, the activation of EMT 
genes can be tumor-specific (Chaffer et al., 2016; Nieto et al., 2016; Saitoh, 2018; Zhang et al., 2016). 
For example, NFκB can increase Snail expression in breast, colon, and pancreas cancer cells (Barbera 
et al., 2004; Baulida et al., 2019; Cichon and Radisky, 2014; Ordonez-Moreno et al., 2017), while in 
atypical teratoid/rhabdoid and liver tumor cells, the activation of Snail is mainly done by STAT3 (Liu 
et al., 2015; Saitoh et al., 2016; Zhou et al., 2017). Furthermore, it was shown in pancreatic 
adenocarcinomas that EMT is rather induced by an alternative program that is based on the 
internalization of essential proteins, rather than the induction of a genetic program. Importantly, tumor 
cells undergoing an EMT program based on post-translational processes displayed a different 
migration in cell clusters instead of single cells. Such behaviour was also observed in breast and 
colorectal cancers (Aiello et al., 2018). 
4.3 E/m-type CTCs have the highest capacity to form lung metastasis 
In order to assess the potential of CTCs to form metastases when they are in the blood stream, i.v. 
injections were performed in BALB/c mice. Nineteen days following i.v. injection of E-type (4T1), 
E/m-type (CTC6-6, CTC6-11, CTC8-12, DTC1), M/e-type (CTC8-6, CTC8-5, CTC8-1), and M-type 
(CTC1) cells, we found that E/m-type CTCs have the significantly highest capacity to generate lung 
metastases. These findings are in line with the emerging notion that carcinoma cells with a partial 
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rather than a full EMT comprise clinically relevant tumor cells, which contribute to metastases 
formation and relapse in general (Aiello and Kang, 2019; Aiello et al., 2018; Kroger et al., 2019; Li 
and Balazsi, 2018; Puram et al., 2018; Puram et al., 2017; Saitoh, 2018). However, since M/e- and M-
type cells had decreased proliferation rates compared with E- and E/m-type cells, we assessed whether 
M/e- and M-type cells have identical lung metastases formation capacities as E- and E/m-type cells 
after longer incubation times in vivo. Interestingly, the second i.v. experiment confirmed that mice 
injected with M/e- and M-type CTCs had a prolonged disease-free survival in comparison with E/m-
type cells (CTC6-6), based on pre-defined parameters including substantial weight loss, weakness, and 
dyspnoea. Importantly, the analysis of sacrificed mice in all injection groups confirmed that E/m-type 
CTCs induced severe lung metastases at early time points, whereas M/e- and M-type CTCs did not or 
barely induce any lung metastases, even at later disease time points. Noteworthy, M/e-type CTCs-
injected mice bore metastases mainly in large bones, but not in the lungs. In breast cancer patients, 
tumor-related deaths are mainly attributed to metastases, especially in the important life-supporting 
organs, such as lung and liver. In contrast, metastases appearing in bones are correlated with relatively 
longer survival time (Siegel et al., 2019). A study analysed the survival of 9143 patients with MBC 
and showed that patients with bone metastasis only had a median overall survival of 38 months (95%CI 
36 - 40). However, the median overall survival significantly decreased to 19 months (95%CI 17 - 20) 
and 17 months (95%CI 16 - 19) in patients with lung or liver metastasis, respectively (Leone et al., 
2017). 
Besides a higher proliferation, E/m-type CTCs have increased adhesion ability to endothelial cells, 
which can promote the cell-cell contact to the blood vessel endothelium and, subsequently, the 
extravasation into lung tissue and the formation of lung metastases (Figure 38). Oppositely, M/e-type 
cells had a reduced ability to attach to endothelium, which may restrain the extravasation and retention 
in lungs and thereby promote the observed formation of metastases in the major sites of large bones. 
The major findings and the deduced working hypothesis are schematically shown in Figure 38. 
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Figure 38: Schema of the influence of EMT on the metastatic process. Cancer cells undergo EMT to different degree (E-, 
E/m-, M/e-, M- type) with decreasing EpCAM expression and increasing chemoresistance. E/m-, M/e-, and M-type cells 
have improved ability to intravasate into blood vessels compared to strongly epithelial 4T1 parental cells. Tumor cells 
present in the blood stream are termed CTCs. E- and E/m-type CTCs have increased adhesion properties, which could 
allow for an improved capacity to extravasate out of blood vessels into distant sites. Tumor cells are termed DTCs when 
they are homing to distant organs (e.g. the bone marrow). In the metastatic sites, E- and E/m-type cells have a better ability 
to proliferate and to regrow as metastases, whereas M/e- and M-type cells are associated with long-term tumor recurrence. 
4.4 The influence of EMT on metastasis 
The EMT is the phenotypic change of epithelial cells to mesenchymal cells, and cells that undergo 
EMT will accordingly change the expression of markers, such as E-cadherin, EpCAM, Vimentin, and 
others (Brabletz et al., 2018b). Former studies demonstrated that EMT was correlated with therapy 
resistance and mesenchymal CTCs were the main cause of resistance towards chemotherapeutic drugs 
(Fischer et al., 2015; Yu et al., 2013; Zheng et al., 2015). The concept that EMT is mandatory for 
metastasis formation itself, is however still under debate. By using cell tracking techniques in an MBC 
and a pancreatic cancer mouse model, two publications proved that metastases-forming tumor cells 
had not undergone EMT and that the EMT transcription factors Snail and Twist were dispensable for 
metastases formation. However, mesenchymal tumor cells were responsible for chemo-resistance in 
both tumor models (Fischer et al., 2015; Zheng et al., 2015). 
In our study, Vimentin was comparably expressed in 4T1 cells and all 4T1-derived cell lines; E-
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cadherin levels differed amongst E-type (4T1), E/m-type (CTC6-6, CTC6-11, CTC8-12, DTC1), M/e-
type (CTC8-6, CTC8-5, CTC8-1), and M-type (CTC1) cells. Furthermore, a comparison between 4T1, 
CTC1 and DTC1 cells showed that the EMT-TFs Twist and Snail were paradoxically higher in 4T1 
cells. Despite new techniques that enable the tracking of EMT-related gene expressions during the 
metastatic process in mouse models (Fischer et al., 2015; Zheng et al., 2015), a comprehensive, all-in-
one tracking of all EMT-related genes is not feasible. For example, using Twist and Snail as referential 
genes in the 4T1 mouse model would fail to recognise EMT-related changes in CTC1 cells. Therefore, 
even tracking the expression of several EMT-related genes, a contribution of EMT during metastases 
formation cannot be terminally excluded (Brabletz et al., 2018a; Ye et al., 2017). 
In the current study, DTC1-drived CTC lines showed diverse EMT phenotypes (EMT scores range 
from 5 to 350), which is a reflection of phenotypic plasticity and an evidence that EMT occurs in CTCs 
and during tumor metastasis. Recently, many studies report the importance of a hybrid or partial EMT 
phenotype in cancer metastasis, which means epithelial tumor cells can benefit from a partial EMT 
program and are not necessary to undergo a complete change to a mesenchymal status (George et al., 
2017; Hiew et al., 2018; Kai et al., 2018; Kroger et al., 2019; Saitoh, 2018). The definition of a partial 
or hybrid EMT phenotype is mostly based on the co-expression of epithelial and mesenchymal 
markers, or gene expression signatures in primary tumors (George et al., 2017; Hiew et al., 2018; 
Kroger et al., 2019; Tan et al., 2014). On the basis of EMT gene signatures, Tan et al. built up an EMT 
scoring system and categorized tumor samples to epithelial-, intermediate-, and mesenchymal-groups. 
From their findings, they concluded that higher EMT scores correlated with poorer survival in patients 
with ovarian and colorectal cancer, but not in patients with breast cancer (Tan et al., 2014). Similarly, 
George et al. developed an EMT scoring metric and classified primary tumors as epithelial-, E/M-, and 
mesenchymal-phenotype. Their result proved that patients with an epithelial-phenotype breast cancer 
had poorer survival in comparison with E/M- and mesenchymal-phenotype tumors, while patients with 
E/M-phenotype lung or ovarian tumors presented poorer outcome as compared to epithelial-
phenotypes (George et al., 2017). 
In cancer cells, EMT is a relative concept and how to define the edges of E and M statuses could 
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substantially influence the definition of EMT subtypes. Therefore, an optimal EMT scoring system is 
still under exploration and it may be tumor-, or even patient-specific.  
Through i.v. injection of E/m-, M/e- and M-type CTCs, we found that the M/e-type cells can form 
metastasis mainly in the big bones instead of the lungs. Theoretically, bone marrow-resident M/e-type 
tumor cells could still release malignant cells in the blood, which could be capable of generating lung 
metastases. Although mice injected with M/e-type cells had tumors in multiple sites, most of them 
remained in the bones and lung metastases were few. This observation is a strong indication that EMT 
has a substantial impact on cancer organotropism. E/m-type cells preferentially metastasized in the 
lung, whereas M/e-type cells usually develop metastases in the bone marrow. Hence, studying 
functional interactions between EMT phenotypes and cancer organotropism should represent a future 
direction. 
4.5 EpCAM expression during tumor metastasis 
EpCAM is an epithelial marker on the cell surface that is widely applied for the capture of CTCs from 
the blood of tumor patients. In order to describe the expression of EpCAM during metastasis formation, 
EpCAM expression levels were tested in all 4T1-derived cell lines. Our results proved that the 
expression of EpCAM was higher in metastatic sites than primary tumors derived from 4T1 cells. 
Similar results on a higher expression level of EpCAM in metastatic sites in comparison with primary 
tumors were demonstrated in a clinical cohort of patients with MBC. Given that the EpCAM level is 
negatively correlated to the degree of EMT in CTCs, the conclusion can be made that compared to 
mesenchymal CTCs (EpCAM-low or -negative), epithelial CTCs (EpCAM-high) have significantly 
higher metastatic ability in the 4T1 mouse model. In accordance with this conclusion, the percentage 
of EpCAM-positive CTCs and, even more pronounced, of DTCs was associated with the presence of 
distant metastases, including lung metastases in patients with MBC. 
In our study, dynamic EMT changes that might occur during the formation of metastases cannot be 
tracked in real-time in tumor cells. Furthermore, EpCAM expression and EMT phenotypes were 
observed in primary tumors, CTCs, DTCs, and metastases at the endpoint of animal experiments. 
Therefore, higher EpCAM levels in metastatic sites could be the result of M/e- or M- type CTCs that 
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have reverted their phenotype through the process of MET, following their homing to distant sites. 
Nevertheless, comparing to energy-consuming MET process (Chaffer et al., 2016; Jolly et al., 2017; 
Nieto et al., 2016), the outgrowth of metastasis directly from epithelial-type tumor cells (i.e. EpCAM-
high, E-, and E/m-type cells) appears more probable. 
The CELLSEARCH system is the most widely used technique for the detection of EpCAM-positive 
CTCs. It has been proved in a wide range of tumors containing breast, lung, colon, and esophageal 
carcinoma, that the numbers of CTCs are correlated to the patients’ outcome (Arrazubi et al., 2019; 
Matsushita et al., 2015; Moussavi-Harami et al., 2014; Qi and Wang, 2017). In our DTC1-derived 
CTC lines, EpCAM represented a suitable surrogate marker for E-, E/m-type systemic cancer cells, 
which defined cells with higher metastatic potential. Hence, using the CELLSEARCH system to 
capture CTCs will certainly lose the information of EpCAM-negative EMT cells, but it can capture 
clinically relevant metastatic cells, i.e. EpCAM positive, E- and E/m-type cells. 
Recently, more and more attention is paid to mesenchymal CTCs, and some studies proved that these 
cells are associated with chemo-resistance (Fischer et al., 2015; Zheng et al., 2015). In the 
chemoresistance assay, M/e- and M-type cells revealed more resistant to Cisplatin and Doxorubicin 
compared to E- and E/m-type cells. In addition to an important missing information concerning the 
total numbers of CTCs, the population of EpCAM-negative or mesenchymal-type CTCs can reflect 
the degree of the EMT process and be a marker for patient’s therapeutic response. Hence, the 
application of EpCAM-independent CTCs/DTCs enrichment technologies is critical to collect the 
complete information of both EpCAM positive and negative systemic tumor cells, but addressed cells 
of utmost clinical relevance. 
4.6 Characterization of CTCs and DTCs isolated by SE-iFISH 
The SE-iFISH technology is based on the aneuploidy status of carcinoma cells and is an EpCAM-
independent CTCs and DTCs isolation method (Lin et al., 2017). Aneuploidy refers to the abnormal 
alteration of chromosomes (including gains and losses) in a cell (Lin, 2018). Somatic aneuploidy is a 
common characteristic of human carcinoma cells (Gordon et al., 2012). Aneuploidy in chromosome 8 
was reported to occur in various solid tumors, for example breast, pancreatic, lung, and colon cancer 
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(Gordon et al., 2012; Lin, 2015, 2018). Such chromosome 8 aneuploidy can be monitored using 
chromosome 8 enumeration probes (CEP8). Using the SE-iFISH technology (Lin, 2015; Lin et al., 
2017), CTCs and DTCs were considered as CEP8-aneuploid cells with a DAPI-positive nucleus, a lack 
of CD45 expression, with or without EpCAM expression. Diploid EpCAM-positive cells can represent 
CTCs and DTCs, but could theoretically also represent normal epithelial cells aberrantly present in the 
blood or bone marrow. Therefore, the impact of the percentage of EpCAM-positive CTCs and DTCs 
on the clinical outcome of patients was assessed including and excluding CEP8-diploid EpCAM-
positive cells. By doing so, it could be demonstrated that independently of the inclusion of CEP8-
diploid EpCAM-positive cells, the percentage of EpCAM-positive cells was prognostic. However, 
following the exclusion of CEP8-diploid EpCAM-positive cells, EpCAM-positive CTCs significantly 
correlated with the presence of lung metastases. Diploid EpCAM-positive cells could be circulating 
endothelial or epithelial cells. Studies confirmed the prognostic value of circulating endothelial cells 
in lung, prostate, rectal, and gastric carcinoma, etc (Bertolini et al., 2013; Gu et al., 2015; Ha et al., 
2013; Najjar et al., 2017). The invasion of surrounding normal vascular or epithelial tissues, and 
rebuilding tumor vessels are important steps for the metastatic cascade, and these events can cause 
increasing numbers of endothelial and epithelial cells in the blood (Garmy-Susini and Varner, 2005; 
Goon et al., 2006; Viallard and Larrivee, 2017). Therefore, including or excluding diploid EpCAM 
positive cells could have only minor impact on the prediction performance of the EpCAM-positivity 
rate. Also, using EpCAM as a surrogate marker for the EMT status, the analysis of systemic tumor 
cells revealed that CTCs contained proportionally more mesenchymal cells, whereas DTCs were 
comprised of more epithelial cells. These results were in accordance with our findings in the 4T1 
mouse experiment, where a broader range of EpCAM expression was observed in CTCs, whereas 
DTCs generally expressed EpCAM to a high level.  
As already mentioned, it remains under debate whether rather epithelial or mesenchymal CTCs 
comprise the major metastasis-inducing cells. Numerous studies support the notion that mesenchymal 
CTCs are correlated with distant metastasis and poorer prognosis (Guan et al., 2019; Li et al., 2017; 
Zhang et al., 2017). On the other hand, using the CELLSEARCH system, former studies confirmed 
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that the numbers of EpCAM-positive CTCs were correlated patients’ outcomes in both non-metastatic 
and metastatic breast cancer (Janni et al., 2016a; Ye et al., 2019). Owing to the fact that current CTC 
enrichment techniques are mainly based on epithelial markers (i.e. EpCAM, EGFR, and Cytokeratins), 
and because it is uncertain which genes will be actually activated within the highly complex EMT 
program in tumors, EMT marker-depending CTC enrichment techniques can hardly reflect the 
complete and actual EMT statuses of CTCs. Furthermore, patients have usually received surgery, 
medication, and/or radiation interventions after the diagnosis of cancer. Epithelial tumor cells are more 
sensitive to chemotherapeutic drugs and could be largely eliminated after chemotherapy (Zhang et al., 
2017). Accordingly, mesenchymal CTCs have been correlated to therapy resistance in vivo, poorer 
outcome, and might be linked to the incidence of long-term recurrences (Li et al., 2017; Yu et al., 
2013; Zhang et al., 2017). Given epithelial CTCs are superior in proliferation and can easily form cell 
clusters and adhere to the endothelium, no matter before or after chemo- or radio-therapy, the 
proportion of epithelial CTCs can be a reliable marker for the acute metastatic risk. In our study, the 
EpCAM-positivity rates were used to reflect the proportions of epithelial cancer cells in CTCs and 
DTCs instead of absolute cell numbers, which represented better the dynamic balance of E and M 
status in CTCs and DTCs.  
In summary, the SE-iFISH technique provides new insights in the study both EpCAM-positive and -
negative systemic tumor cells, and the EpCAM-positivity rates of CTCs and DTCs were correlated 
with the lung metastasis status and overall survival of patients with MBC.
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5. CONCLUSIONS 
5.1. Summary 
In summary, the current study facilitates the understanding of the influence of EMT on breast cancer 
progression and on its role in the formation of lung metastases. In the 4T1 mouse model, it was 
demonstrated that: (1) tumor cells could undergo EMT to variable degree and CTCs with different 
EMT types co-existed within one mouse; (2) E/m-type CTCs primarily contributed to the formation of 
lung metastases; (3) M/e-type CTCs were associated with long-time recurrence in bone marrow in vivo 
and resistance to treatment in vitro; (4) EpCAM expression was negatively correlated to EMT; (5) 
EpCAM expression was higher in metastatic sites (lungs, kidneys, spleens, and lymph nodes) 
compared to primary tumors. 
These results were further verified in a clinical cohort of patients with MBC, where: (1) EpCAM 
expression was likewise higher in metastatic sites (lungs, livers, lymph nodes and bones) compared to 
primary tumors; (2) EpCAM was a useful marker for the epithelial status of systemic tumor cells, 
which allowed to demonstrate a higher proportion of mesenchymal CTCs and epithelial DTCs in 
patients; (3) the EpCAM-positivity rate of CTCs and DTCs (both including and excluding diploid 
EpCAM-positive cells) were associated with the metastatic status of patients and EpCAM-positive 
DTCs correlated with 6-months and overall survival. All in all, epithelial-type (EpCAM-positive) 
systemic tumor cells with a restricted mesenchymal transition are the major metastasis-initiating cells 
in breast cancer. 
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5.2. Zusammenfassung 
Die Bildung von Metastasen bei Patienten mit soliden Tumoren stellt das größte Risiko für eine 
schlechte Prognose dar. Karzinomzellen durchlaufen eine epitheliale-mesenchymale Transition 
(EMT), welche für die Bildung von Metastasen verantwortlich gemacht wurde. Der exakte 
Beitrag einer EMT-induzierten Tumorzellheterogenität zum Krankheitsverlauf wird dennoch 
kontrovers diskutiert. Insbesondere der Einfluss der EMT auf das metastatische Potenzial 
systemischer Tumorzellen im Blut und im Knochenmark von Patienten ist bislang unzureichend 
untersucht. In der vorliegenden Arbeit wurde der EMT-Status bei ex vivo kultivierten 
zirkulierenden und disseminierten Tumorzellen (CTC/DTC) aus dem Blut bzw. Knochenmark in 
einem Mausmodell des metastasierten Brustkrebses untersucht. Epitheliale CTC mit einem 
unvollständigen mesenchymalen Übergang (E/m-Type) besaßen die stärkste Fähigkeit zur 
Bildung von Lungenmetastasen, wohingegen mesenchymale CTC mit einer geringen epithelialen 
Transition (M/e-Type) eine stark eingeschränkte Fähigkeit zur Metastasierung aufwiesen. Im 
Folgenden diente die Expression des epithelialen Zelladhäsionsmoleküls EpCAM als 
Surrogatmarker zur Bewertung der EMT-Heterogenität von klinischen Proben von Patienten mit 
metastasiertem Brustkrebs, einschließlich Metastasen, CTC und DTC. Die vermehrte 
Anwesenheit epithelialer CTC und insbesondere epithelialer DTC im Blut bzw. im Knochenmark 
dieser Patientinnen korrelierte mit dem Auftreten von Fernmetastasen und mit einem signifikant 
schlechteren klinischen Verlauf. 
Diese Studie fördert grundlegend das Verständnis des Beitrags der EMT zur Ausbildung von 
Metastasen und untermauert den heterogenen EMT-Phänotypen von Tumorzellen als wichtigen 
Parameter für die Tumorprognose und -behandlung. Wir schlagen ferner vor, dass EpCAM-
abhängige CTC-Isolationssysteme die CTC Zahlen im Blut von Patienten unterschätzen, jedoch 
klinisch relevante metastatische Zellen quantifizieren.
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9. ABBREVATIONS 
 
Abbreviation Annotation 
°C Celsius degree 
6-TG 6-Thioguanine 
bp Base pairs 
BSA Bovine serum albumin 
CD Cluster of differentiation 
cDNA Complementary DNA 
CEP8 Chromosome 8 
CK Cytokeratin 
CT Computed tomography 
CTCs Circulating tumor cells 
ddH2O Double distilled water 
del Deletion 
der Derived 
DMEM Dulbecco`s Modified Eagle Medium 
dmin Double minute chromosomes 
DMSO Dimethylsulfoxid 
DNA Desoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP Desoxyribonucleotidtriphosphate 
DTCs Disseminated tumor cells 
E Epithelial 
E/m Epithelial/mesenchymal 
EGFR Epidermal growth factor receptor 
EMT Epithelial to mesenchymal transition 
EMT-TFs EMT-transcription factors 
EpCAM Epithelial cell adhesion molecule 
EpEX Extracellular domain 
EpICD Intracellular domain of EpCAM 
ERK Extracellular signal regulated kinases 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum 
FDA Drug Administration 
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Abbreviation Annotation 
FITC Fluorescein isothiocyanate 
g Gravity 
gDNA Genomic DNA 
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h Hour 
H2O Water 
Her2 Human epidermal growth factor receptor 2 
IC50 The half maximal inhibitory concentration 
IHC Immunohistochemistry 
i.v Intravenous injection 
KCl Potassium chloride 
kDa Kilo Dalton 
L Litre 
LMP Agarose Low Melting Point Agarose 
M Mesenchymal 
M/e Mesenchymal/epithelial 
mA Milli ampere 
mar Marker chromosome 
max Maximal 
MBC Metastatic breast cancer 
MET Mesenchymal to epithelial transition 
MFI-R Mean fluorescence intensity ratio 
mg Milligram 
MIC Metastases-inducing cell 
min Minute 
mL Millilitre 
mM Millimolar 
MRI Magnetic resonance imaging 
MTT Thiazolyl Blue Tetrazolium Bromide 
NaCl Modium chloride 
nm Nanometer 
OD Optical density 
PBS Phosphate buffered saline 
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Abbreviation Annotation 
PCR Polymerase chain reaction 
PI Propidium iodide 
qRT-PCR Quantitative Real Time PCR 
RBC Red blood cell 
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RNAse Ribonuclease 
rob Robertsonian translocation 
ROC curve Receiver operating characteristic curve 
rpm Revolutions per minute 
RT Reverse transcriptase 
RT-PCR Reverse transcription PCR 
SCC Single cell clone 
SE-iFISH 
Subtraction enrichment and immunostaining-fluorescence in situ 
hybridization 
sec Seconds 
siRNA Small interfering RNA 
T Thymidine 
t Translocation 
TBS Tris buffered saline 
TIC Tumor-initiating cells 
TNF Tumor Necrosis Factor 
UICC Union for International Cancer Control 
V Volt 
μg Microgram 
μL Microlitre 
μm Micrometer 
μM Micromolar 
WB Western blot 
WBC White blood cell 
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